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Natural products have historically served as a major source for most of the therapeutically 
relevant compounds. A significant fraction of these natural product-based drugs and leads are 
derived from microorganisms. Although the traditional culture-based strategy has proven very 
successful over the course of more than a century of investigation, it excludes a significant 
portion of the molecules present in environmental samples because majority of the bacteria are 
not readily amenable to culture-based strategies. This uncultured majority is believed to 
represent 99% of bacterial species in the environment. Therefore, it has remained a significant 
challenge to access the chemical diversity present in these microorganisms using culture-based 
methods. Most modern natural product discovery efforts are faced with the hurdle of high 
rediscovery rates (>99%) of known metabolites produced by easily cultured bacteria.  
 
Metagenomics has evolved as an alternative approach to conventional microbial screening. By 
directly cloning environmental DNA (eDNA or metagenome) in a surrogate host, one can 
exhaustively investigate the metagenome, independent of the culturability of the source 
organisms. Metagenomic approaches can thus provide access to previously untapped pools of 
chemical diversity. These techniques have been employed in the current thesis to search for a 
family of therapeutically relevant, polycyclic aromatic natural products, synthesized by Type II 
polyketide synthases (PKSs) in soil-borne bacteria. Through the functional characterization of 
soil eDNA-derived Type II PKS containing clones, herein we attempt to identify novel PKS 
systems that encode structurally diverse metabolites and explore their biological activity 
(Chapter 1).  
 
My doctoral work towards the discovery of novel type II PKS derived natural products has led to 
the elucidation of the mode of action of eDNA encoded antibiotics Fasamycins A and B. To 
identify the target of the fasamycins, fasamycin A resistant mutants were generated. Next-
generation sequencing of these mutants, along with in vitro biochemical assays, showed that 
fasamycins inhibit the FabF gene of the type II fatty acid biosynthetic system. Subsequently, 
candidate gene overexpression studies consolidated the mode of action of fasamycins. (Chapter 
2)   
 
Insights into the genomes of uncultured microorganisms indicate that they are rich in Type II 
PKS gene clusters. In our attempt to identify novel aromatic polyketide natural products, we 
investigated the eDNA of soil samples collected from Texas region for unique Type II PKSs 
using homology-based metagenomic screening techniques. The eDNA-derived clones containing 
unique type II polyketide synthase genes identified in this screening were examined for the 
ability to produce clone-specific metabolites in Streptomyces. This led to the identification of 
hitherto unknown biosynthetic gene cluster for Seitomycin, a Type II PKS derived antibiotic. 
(Chapter 3) 
In addition to the work using homology-based metagenomic techniques outlined above, three 
unique Type II PKS clones were identified based on bioinformatics analysis and comparison 
with previously characterized PKS gene clusters. These novel pathways were functionally 
reconstructed from multiple overlapping clones using Transformation Associated Recombination 
(TAR). Upon complete reassembly, all of the three PKS pathways were demonstrated to produce 
clone-specific metabolites during heterologous expression studies in Streptomyces host. In future 
studies, characterization of these metabolites is likely to lead to novel Type II PKS derived 
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Introduction and Background 
 
1.1 Natural Products 
Throughout most of history, small molecule natural products have been a source of novel 
therapeutics for a wide spectrum of diseases. Since the early 1800s, discovery of natural products 
has started a new era of medicine where drugs could be purified from plants or microorganisms 
and administered in precise dosage. The term natural product really means any naturally 
occurring substance but is generally taken to mean a secondary metabolite - a molecule that has 
no essential function in metabolism. It’s thought that these chemicals exist to increase the 
likelihood of an organism’s survival by attracting or repelling other organisms. Among the first 
reported examples of natural products were strychnine, morphine, atropine, quinine, and 
colchicine. In 1826, E. Merck developed the first commercial natural product, morphine, and this 
was followed by the first semisynthetic, pure drug based on a natural product, aspirin, by Bayer 
in 1899.  
The next milestone was the discovery of penicillin from the filamentous fungus Penicillium 
notatum by Alexander Fleming in 1929.  This truly ushered in the “Golden Age of Antibiotics”, 
the time period from the 1940s to the 1970s. Pharmaceutical companies launched extensive 
investigations of microbes as sources of novel antibiotics and led to the discovery of a host of 
other antibacterial antibiotics, including the tetracyclines (e.g., doxycycline), cephalosporins, 
aminoglycosides (e.g.,streptomycin), lipopeptides (e.g., daptomycin), glycopeptides (e.g., 
vancomycin), and macrocyclic compounds such as erythromycin. (Newman et al. 2000, Cragg 
	 2 
and Newman 2001). Microbial natural products have also been the source of other anti-infective 
drugs in the form of antibiotics having antifungal (e.g., amphotericin, nystatin) and antiparasitic 
(e.g., ivermectin, fumagillin) activities. (Newman et al. 2000, Cragg and Newman 2001, 
Newman and Cragg 2012). Microbes have provided the template for the development of 
anticholesterolemic drugs, known as statins. The discovery of the fungal metabolites mevastatin 
(compactin) and lovastatin as inhibitors of HMG-CoA reductase led to the development of 
synthetic statin analogues, such as lovastatin and simvastatin (Mevacor). Antitumor antibiotics 
such as anthracyclines (e.g., doxorubicin), enediynes (e.g., calicheamicin), ansamycins (e.g., 
geldanamycin), peptolides (e.g., dactinomycin), epothilones (e.g., ixabepilone), mitosanes (e.g., 
mitomycin C), etc. are all microbial natural products that continue to play significant role in the 
drug discovery and development process. (Newman and Cragg 2012, Cragg et al. 2009, Cragg et 
al. 2012). Rapamycins are another important class of immunosuppressive drugs that complement 
the role of another microbial metabolite cyclosporine. (Cragg and Newman 2001). It is estimated 
that almost 70% of the small molecule drugs have their origin in natural products. (Newman and 
Cragg 2007). Thus, natural products have been, and continue to be, an indispensable source of 
novel drugs and pharmaceutical leads for the treatment of many human diseases.  
Natural products isolated from cultured organisms have provided a large proportion of the most 
important pharmacophores discovered to date (Figure 1) (Newman, Cragg et al. 2003; Newman 
and Cragg 2004; Newman and Cragg 2007). Their bioactivity is attributed, to a large extent, to 
selective pressures that culminated in the evolution of structural and chemical properties of 
natural products to function effectively in biological contexts. In the native microbial hosts, the 
metabolites have been shown to play critical roles in processes like self-defense, nutrient 
scavenging and virulence. (Omura, Ikeda et al. 2001; Wolfgang, Kulasekara et al. 2003; 
	 3 
Nougayrède, Homburg et al. 2006; Wyatt, Wang et al. 2010). Soil-dwelling bacteria, especially 
actinomycetes, have been an abundant source of bioactive natural products. In fact, an estimated 
two thirds of all clinically useful antibiotics come from one bacterial genus alone, Streptomyces 
(Kieser et al. 2000). As a single gram of soil is predicted to harbor over 10,000 individual 
bacterial species, soil-bacteria seem to represent a promising reservoir of novel natural products 
with tremendous therapeutic potential (Torsvik et al. 1990; Curtis et al. 2002; Rappe and 
Giovannoni 2003) 
   
There are hundreds of thousands of different natural products reported in literature. The CRC 
Dictionary of Natural Products (DNP) lists 190,939 records (DNP, Chapman and Hall, 2005). 
There is no rigidly defined scheme for classifying natural products. Their immense diversity in 
structure, function and biosynthesis is too vast to allow them to fit into a few simple categories. 
However, widely accepted are five major classes of natural products: ployketide, non-ribosomal 
peptides, alkaloids, terpenoids and enzyme co-factors.  
1.1.1 Polyketides 
Polyketides represent one of the largest families of secondary metabolites, especially abundant 
among actenimycete bacteria, eukaryotic fungi and higher plants. They are a highly diverse 
group of natural products having structurally intriguing carbon skeletons, which comprises 













































polyphenols, macrolides, polyenes, enediynes and polyethers. Although their exact roles in 
biological contexts are not known in all cases, it is believed that they function as pigments, 
virulence factors, infochemicals, or for defense. From a pharmacological viewpoint, polyketides 
are an important source of novel therapeutics. In particular, they are used in medicine mainly as 
antibiotics, immunosuppressants, antiparasitics, cholesterol-lowering, and antitumor agents. 
(O’Hagan 1991). Some notable examples include tetracyclines and erythromycin (antibiotics), 
doxorubicin (anti-cancer), avermectin and monencin (antiparasitics), FK506 (immuno-
suppressant), all from the bacterial group that produces a large proportion of such compounds, 
the actenomycetes. 
These molecules are biologically synthesized by multifunctional polyketide synthases (PKSs), 
which catalyze repeated decarboxylative condensations between acyl thioesters (usually acetyl, 
propionyl, malonyl, or methylmalonyl) (Figure 2). Whereas the total chemical synthesis of 
polyketides is highly challenging, it is remarkable that their vast structural and functional 
diversity results from the controlled assembly of some of the simplest biosynthetic building 
blocks. Since the first biosynthetic investigations by Collie, who also coined the term 
‘polyketide’, and the acetogenin hypothesis by Barton (Staunton and Weissman 2001), 
biosynthesis of polyketides has become a fertile area of research and discovery. With emerging 
techniques in molecular biology (Hopwood 1997), it has now become possible to understand the 
biosynthetic logic of polyketide diversity, and engineer biosynthetic pathways for the production 
of novel drug candidates. (Wilkinson and Micklefield 2007, Weissman and Leadlay 2005).  
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On the basis of architecture type and mode of action of the assembly lines, PKSs are classified in 
various types (Figure 3). Type I refers to linearly arranged and covalently fused catalytic 
domains within large multifunctional enzymes, where as the term type II indicates dissociable 
complex of discrete and usually monofunctional enzymes. Furthermore, a third group of 
multifunctional enzymes of the chalcone synthase type is denoted as type III PKSs (Figure 3). 
Aside from the structures of the enzymes or enzyme complexes, the PKSs are also categorized as 
iterative or non-iterative, that is, whether or not each KS domain catalyze more than one round of 
elongation.  
1.1.2. Type II polyketides 
A number of polycyclic aromatic natural products are synthesized by polyketide synthases 
(PKSs) in soil-borne bacteria. They exhibit anticancer (e.g. doxorubicin), antibacterial (e.g. 
oxytetracycline), antifungal (e.g. pradimicin), antiviral (e.g. A-74528), antiparasitic (e.g. 
frenolicin) and other related activities. These PKSs, also called type II PKSs because of their 
relationship to type II fatty acid synthases from bacteria and plants, are a fascinating family of 
multifunctional catalysts that synthesize a wide range of interesting and medicinally important 












































Figure 2. Polyketide biosynthesis: Concatenation of acetate units during polyketide biosynthesis, 
the decarboxylation of malonyl-CoA (or methylmalonyl-CoA), generates a nucleophilic enolate 
thioester which attacks an acyl thioester (or other starting unit) in a Claisen condensation 
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Iterative type II PKS systems are common in prokaryotic organisms. Methods for genetic 
manipulation of Gram–positive actinomycetes, pioneered by D. A. Hopwood and coworkers, 





































































AT: acyl transferase   ACP: acyl carrier protein   KS: keto synthase   KR: keto reductase   DH: dehydratase  
ER: enoyl reductase    TE: thioesterase 
Figure 3. Following the reaction similarity with fatty acid synthases (FASs), PKSs are classified into three types, 
type I, type II, and type III, based on their enzyme architecture. Type I PKSs consist of large multifunctional 
proteins with individual functional domains. These are further classified into single modular iterative type I PKS 
(iPKS) and multi-modular PKS (mPKS) in which one module consists of a set of catalytic enzyme domains (such 
as ketosynthase (KS), acyltransferase (AT) and acyl carrier protein (ACP), at the minimum), together with other 
modification domains. Type II PKSs consist of individual separate dissociable enzymes that form a multi-enzyme 
complex to carry out the reaction similar to bacterial FASs. In contrast to these multi- functional or multi-enzyme 
systems, type III PKSs are enzymes that maintain a simple architecture, i.e. a homodimer of condensation 
subunits, corresponding with KS domains of other types of PKS. This type of PKS uses acyl-CoA thioester 
directly, without using ACPs. Therefore, type III PKSs are the smallest and so-far well characterized in PKSs .  
	 7 
sequencing of a number of aromatic polyketide biosynthetic gene clusters. For example, the 
complete act gene cluster responsible for actinorhodin biosynthesis was cloned in 1984 
(Malpartida and Hopwood 1984), and its PKS genes were fully sequenced by 1992 (Fernandez-
Moreno, et al.  1992). A ketosynthase (KS), chain length factor (CLF) and acyl carrier protein 
(ACP) are encoded within the act gene cluster; these subunits were designated the ‘minimal 
PKS’ (Figure 3). Additional PKS subunits, including ketoreductases (KR), cyclases (CYC), and 
aromatases (ARO) define the folding pattern of the nascent poly-beta keto intermediate. In




































































































































































Figure 4. Cyclization pattern of bacterial type II PKS derived polykitedes. On the basis of the carbocycles produced 
by polyketide folding and condensation, type II PKS products are further classified into various subtypes.  
	 8 
almost all type II polyketide pathways, cyclases mediate polyketide cyclization to generate the 
aromatic ring system (Figure 4). Studies indicate that the first cyclization (i.e. C9–C14 or C7–
C12) is regulated by the PKS and the presence or absence of a KR has some impact on the 
preformation of a bend in the carbon chain. Cyclase functions are attributed to individual 
cyclization steps, such as second and third ring formation, and so on. While cyclases catalyze 
specific aldol condensations, aromatases support the cyclodehydration process (Hertweck 2009) 
(Figure 4). Given the clinical and commercial success of a diverse collection of aromatic 
compounds that arise from iterative type II polyketide synthases, considerable interest has 
developed to gain access to these microbial secondary metabolites. Accessing this particular 
class of polyketide natural products is the primary focus of the current doctoral work.  
1.2. Metagenomics and uncultured microorganisms 
Charting biologically relevant chemical space is of utmost importance for drug discovery and 
development. However, the discovery of new natural product antibiotics has declined over the 
past several decades (Fox 2006). There is more than one factor contributing to this decline. The 
isolation of small molecules from bacteria or fungi from environmental sources mostly relies on 
the decade-old methods and techniques (Figure 5). The traditional protocol used to isolate and 
identify natural products from bacteria is to first culture an individual bacterium from the 
environment, extract bacterial cultures using organic solvents, and isolate pure compounds 
through activity-guided fractionations (Figure 5). However, the traditional culture-based 
paradigm itself seems to be one of the major hurdles to new natural product discovery. Despite 
decades of historical productivity, pharmaceutical companies have recently deemphasized 
natural product discovery efforts due to the increasing rediscovery rates of common metabolites 
produced by easily cultured bacteria - a rate that now exceeds 99%. (Newman et al. 2004, 
	 9 
Newman et al. 2007, Newman et al. 2012). The difficulties associated with culturing 
environmental bacteria prevent traditional culture-dependent methods from being applied to a 
significant fraction of the bacterial species found in nature. Microbial 16S rRNA sequencing 
efforts indicate that only a small fraction of the world’s environmental microbes have been 
cultured using standard microbiological methods. (Torsvik et al. 1990, Kaeberlein et al. 2002, 
Zengler et al. 2002, Gans et al. 2005, Tringe et al.  2005). From the bacterial kingdom, this 
minority is believed to represent less than 1% of all species in existence. These same analyses 
also indicate that more than 80 major bacterial divisions exist, but only less than half are 
represented by cultured isolates. (Schloss et al. 2004, Keller et al.  2004, DeSantis et al. 2006). 
Such insights suggest that uncultured bacteria are likely the largest remaining pool of genetic and 
chemical diversity on the planet. Thus, it is apparent that the vast majority of natural products 
produced by microorganisms found in the biosphere are beyond the scope of the traditional 
culture-dependent paradigm.  
                        

















Figure 5. Microbial natural product isolation: Traditional culture-based method. Cultured 
environmental samples (in this example, bacteria) are isolated and crude extracts are generated. 
Iterative rounds of fractionation and activity assays are used until a pure compound is obtained for 
structural elucidation. 
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methods, which are now being developed to access this untapped reservoir of chemical diversity. 
Typically, culture-independent strategies involve direct cloning of the genetic material from an 
environmental sample, which contains the genes encoding for small molecule (Figure 6). The 
genetic diversity of all the bacteria in any given environmental sample has been termed the 
“metagenome” (Handelsman, Rondon, Brady, et al. 1998). While genomics is the study of an 
individual organism's DNA, metagenomics transcends the individual genome. Taking advantage 
of the advances in DNA-sequencing technology, this new approach allows the study of entire 
communities of microbes simultaneously, bypassing the need for isolation and culture. It 
therefore seems likely that we can capture the biosynthetic potential of uncultured bacteria 
through metagenomics and gain access to unidentified bioactive metabolites for future drug 
discovery efforts. Metagenomics is fast evolving as an alternative to conventional microbial 
screening for natural product discovery. 
Studying natural product gene clusters using metagenomic techniques requires eDNA 
(environmental DNA) cloning and sequence enrichment techniques. DNA extracted from 
environmental sample, such as soil and water, contains large quantities of genetic material, 
including secondary metabolite biosynthetic gene clusters (Figure 6). DNA extracted from 
environmental sample, such as soil and water, contains large quantities of genetic material, 
including secondary metabolite biosynthetic gene clusters. This eDNA is purified and cloned 
into a vector that allows the high efficiency transformation of a tractable library host, typically E. 
coli. To accomplish this, eDNA can be ligated into a cosmid vector, packaged into lambda phage 
and transfected into E. coli (Brady 2007). This cloning method can captures up to 50 kb pieces of 
eDNA in a single clone. Since the genes responsible for the biosynthesis of natural products are 
typically clustered together, it is possible to capture an entire biosynthetic gene cluster or a large 
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part of it on a single cosmid (Handelsman, Rondon, Brady et al. 1998).  
 
    
 
Metagenomic methods are universally applicable and have already been applied to microbial 
communities from soils/sediments (Rondon et al. 2000; Brady et al. 2002; Voget et al.  2003), 
rumen gut (Brulc et al. 2009), planktonic marine microbial assemblages (Beja et al. 2000, 
Breitbart 2002), deep sea microbiota (Sogin et al. 2006), an acid mine site (Tyson et al.  2004), 
arctic sediments and the Sargasso Sea (Venter et al. 2004). The foundation of all metagenomic 
approaches is the isolation and subsequent examination of DNA extracted directly from naturally 
occurring microbial populations, which avoids the difficulties associated with culturing 
environmental bacteria (Handelsman et al. 1998). As previously mentioned, secondary 
metabolite biosynthetic gene clusters are often clustered in the bacterial genome. Metagenomics 
is particularly appealing to natural product researchers because of this characteristic clustering, 
since most secondary metabolite biosynthetic gene clusters are under 100 kb, making it possible 
to capture biosynthetic gene clusters on individual or, at most, a small number of overlapping 
eDNA clones (Handelsman et al. 1998).  Large scale cosmid cloning of environmental DNA 
therefore provides a platform from which one can investigate secondary metabolite biosynthetic 



















Figure 6. Metagenomic library construction and screening: eDNA is purified and cloned into a vector that 
allows high efficiency transformation into a culturable library host. One of two primary screening 
methodologies (functional/homology-based) are used to identify clone-specific molecules or biosynthetic 
gene clusters for downstream heterologous expression and characterization efforts.  
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1.2.1. Functional metagenomic screening 
One approach to access the chemical diversity of uncultured microbes is through expression-
dependent or functional screening (Figure 6). In functional metagenomic studies, eDNA libraries 
are examined in simple high throughput assays designed to identify clones that have phenotypes 
traditionally associated with the production of small molecules, such as pigment production, 
antibiosis, or altered colony morphology. One of the simplest strategies used to detect eDNA 
clones that might produce small molecule antibiotics has been to screen libraries hosted in E. coli 
for clones that generate zones of growth inhibition against test microbes in top agar overlay 
assays. The isolation of clone specific metabolites produced by active eDNA clones identified 
from bacterial top agar overlay assays has led to the characterization of a variety of new 
longchain N-acylated amines (3), as well as a new isonitrile functionalized indole antibiotic (5) 
(Figure 7) (Brady and Clardy 2000; Brady and Clardy 2005). Antibiotics have also been found 
by examining pigmented eDNA clones, and also through the direct examination of fermentation 
extracts from randomly selected clones (Wang, Graziani et al. 2000; Brady, Chao et al. 2001; 
MacNeil, Tiong et al. 2001; Gillespie, Brady et al. 2002; Lim, Chung et al. 2005; Long, Dunlap 
et al. 2005). Compounds with bioactivity identified from these types of studies include the 
antibiotic pigments violacein (2) and indigo (1) all recovered from soil libraries (Figure 7).  
 
Functional metagenomics has also been used to identify clones that produce proteins with 
potential anti-infective properties (Schipper, Hornung et al. 2009). Although nearly all small-
molecule-focused functional metagenomic studies have been carried out in E. coli, it is likely 
that the majority of the biosynthetic diversity present in an environmental sample is not 
functionally accessible using the same heterologous host. A computational analysis of promoters 
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and ribosomal binding sites used by a taxonomically diverse group of sequenced bacteria found 
that at most, 40% of the enzymatic activities present within a typical metagenomic sample could 
be accessed using E. coli as a heterologous host (Gabor, Alkema et al. 2004). Therefore, libraries 
initially constructed in E. coli were later shuttled into different hosts including S. lividans, 
Ralstonia metallodurans, Rhizobium leguminosraum, Agrobacterium tumefaciens, Burkholderia 
graminis, Caulobacter vibrioides, and Pseudomonas  putida (Wang, Graziani et al. 2000; 
Martinez, Kolvek et al. 2004; Li, Wexler et al. 2005; Craig, Chang et al. 2009; Craig, Chang et 
al. 2010).  
         
                       Figure 7. Natural products identified through functional metagenomic screening 
 
Functional metagenomic screening strategies have been used to identify eDNA clones carrying 
natural product biosynthetic gene clusters. One primary advantage of a functional screen is that 
no a priori knowledge of the biosynthetic enzymes is required to discover novel metabolites. In 
functional screens, a secondary metabolite is directly linked to its biosynthetic genes allowing 
the unbiased discovery of novel biosynthetic sequences that have not been characterized before. 



































expression of entire biosynthetic gene clusters requires the coordinated production of multiple 
proteins in a clone under laboratory culture conditions. Because the gene clusters isolated from a 
metagenomic sample are of diverse phylogenetic origin, the likelihood that a gene cluster meets 
all of these requirements is very low, and hit rates for functional screens of metagenomic 
libraries are generally around 0.01% (Courtois, Cappellano et al. 2003; Williamson, Borlee et al. 
2005; Guan, Ju et al. 2007; Brady, Simmons et al. 2009). Due to these limitations, functional 
screens of metagenomic libraries have been designed so that they can be easily carried out on a 
large number of clones.  
 
Although functional metagenomic screening is a powerful technique to gain access to the 
chemical diversity encoded in uncultured microorganisms, this strategy still requires some 
optimization. As described earlier, metagenomic cloning relies primarily on cosmid-based 
vectors. However, many canonical biosynthetic gene clusters are too large (>50 kb) to be 
captured on single cosmids and are truncated. This technical hurdle presents a major limitation of 
using functional assays to discover new natural products from cosmid-based eDNA libraries. 
Aside from this, the diversity present in environmental microbiomes makes the selection of an 
optimal heterologous screening host quite challenging (Torsvik, Øvreås et al. 2002). 
Heterologous expression hosts are inherently limited in their capacity to functionally process 
foreign DNA. The expanded use of phylogenetically diverse heterologous expression hosts will, 
therefore, most likely continue to benefit functional screening efforts. Exploring vector-host 
pairs that allow for the screening of metagenomic libraries in phylogenetically diverse 
microorganisms have the potential to expand the chemical diversity accessed through functional 
metagenomic studies. 
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1.2.2. Homology based screening 
Expression-independent or homology-based screening of metagenomes is based on PCR 
amplification of conserved natural product biosynthetic gene sequences to identify and recover 
gene clusters from environmental DNA (eDNA) libraries. This allows targeted recovery of 
specific biosynthetic pathways from the genomes of all bacterial species present within an 
environmental sample.  
Homology-based screens rely on the homology of the unknown, eDNA-derived secondary 
metabolite biosynthetic pathways to sequenced clusters of known metabolites. In these studies, 
eDNA libraries are probed to identify clones that contain conserved sequences associated with 
secondary metabolite biosynthesis. Bioinformatics analyses of sequences recovered through 
homology screening allow for the exclusion of sequences that are likely associated with gene 
clusters encoding for previously encountered metabolites, significantly reducing the likelihood 
for redundant isolation and increasing the likelihood of finding hitherto rare metabolites. Thus, 
homology-based screening coupled with phylogenetic analyses of sequences captured in large 
eDNA libraries should permit routine discovery of biosynthetic gene clusters encoding for 
metabolites belonging to even previously rare families of bioactive natural products. 
 
Homology-based screening utilizes degenerate oligonucleotides to amplify sequence homologs 
via the polymerase chain reaction (PCR) (Seow, Meurer et al. 1997).  Degenerate PCR primers 
are designed from previously sequenced conserved regions of a biosynthetic gene of interest. 
Screening metagenomic libraries with these degenerate primers enables the identification and 
recovery of individual clones with homologous genes from an eDNA library. These type of 
screening can be used to find new derivatives of known metabolites by targeting pathway-
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specific biosynthetic genes. These primers can also be designed to identify novel structures by 
targeting conserved general biosynthetic genes found in a class of compounds. For example, 
degenerate primers based on conserved regions of minimal PKS KSα gene are used to amplify 
KSα sequences captured in the Texas eDNA library. The unique  (<85% identity to previously 
known KSα genes) eDNA-derived KSα sequences then used as probes to identify and recover the 
cosmid clones containing type II PKS biosynthetic gene clusters from the metagenomic library 
(Figure 8).  There have been multiple reports in the literature describing the identification of 
novel metabolites derived from type II PKS biosynthetic systems from eDNA samples 
(Hertweck 2009).  
 
 
1.2.2.1. Novel metabolites  
Homology-based metagenomic screening is proving to be a rewarding avenue to access the 
structural diversity encoded by uncultured bacteria. It has been successfully used to find novel 
structures by targeting conserved general biosynthetic genes found in a class of compounds. One 























KSα$ degenerate$ primer$ sequences$ and$ their$ annealing$ sited$ on$
minPKS.$KSa$=$b+ketoacyl$synthase;$KSβ$=$chain$length$factor;$ACP$
=$acyl$carrier$protein$
Figure  8. PCR-based screening for novel natural products (type II PKS): Degenerate PCR primers 
designed to recognize a conserved region in KSα sequences from minPKS were used to amplify 
partial KSα sequences from eDNA (Wawrik et al. 2005).  
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polyketides. Type II polyketides utilize a small collection of biosynthetic enzymes to generate a 
diverse array of scaffolds, which are modified by various downstream enzymes. Although the 
gene clusters that encode the biosynthesis of these diverse metabolites can differ substantially in 
gene content, they all encode a highly conserved minimal PKS composed of three proteins:  
    
Figure 9. Metabolites isolated in homology-based metagenomic screening.  A number of aromatic polyketides have 
been isolated from soil eDNA libraries. 
ketosynthase alpha (KSα); ketosynthase beta/chain length factor (KSβ); and acyl carrier protein 
(ACP). This “minimal PKS”, which is responsible for the iterative condensation of malonyl-CoA 
into a nascent polyketide chain, possesses a conserved organization, and is therefore an ideal 
target to identify using homology-based metagenomics (Macpherson et al. 1994). The 
examination of eDNA libraries and metagenomic sequencing data for relatives of known 
biosynthetic systems is likely to be a generally applicable strategy for identifying new structural 
variants of many bacterially derived antibiotics, potentially providing ready access to compounds 
with improved spectrum of activity (Figure 9). Kang and Brady recently identified a collection of 
novel bioactive pentangular polyphenols, calixanthomycin A, arenimycins C-D, 





























































screening. Using similar strategy, the antibiotic fasamycins (6) were isolated from soil and found 
to inhibit FabF of type II fatty acid biosynthesis (Feng, Kallifidas et al. 2011; Feng, Chakraborty 
et al. 2012). King et al. expressed a pathway encoding for the biosynthesis of a type II polyketide 
and characterized a new molecule erdacin (8) (King et al 2009) with previously unknown 
pentacyclic skeleton, lending credence to the idea that uncultured bacteria may contain chemical 
diversity unlike that seen in cultured bacteria (King et al. 2009). A collection of fluostatins (7) 
and the methicillin-resistant Staphylococcus aureus (MRSA)-active antibiotic tetarimycin A (9) 
have also been isolated from soil libraries (Feng, Kim et al. 2010; Kallifidas, Kang et al. 2012) 
(Figure 9). In addition to isolating type II polyketides, homology-based metagenomic screening 
has been successfully used to identify novel tryptophan dimer analogues from eDNA libraries 
(Chang et al. 2015, Chang and Brady 2014, Chang et al. 2013, Chang and Brady 2011).  
1.2.2.2. Congeners of known metabolites 
Homology-based metagenomic approaches have been used in a number of studies to identify 
new derivatives of known compounds (Donia, Hathaway et al. 2006; Schmidt and Donia 2009; 
Ziemert, Ishida et al. 2010). Banik et al. employed a PCR screen targeting OxyC, a glycopeptide 
oxidative coupling enzyme, to identify a number of glycopeptide biosynthetic gene clusters from 
soil eDNA libraries (Banik and Brady 2008; Banik, Craig et al. 2010) that produced novel mono, 
di- and trisulfated glycopeptide congeners from the teicoplanin aglycone (11) (Figure 10) (Banik 
and Brady 2008). In another homology-based metagenomic study, Kang et al. identified an 
eDNA-derived cluster encoding for arimetamycin A (12), an anthracycline found to be more 
potent than clinically used natural anthracyclines against multidrug-resistant cancer cells (Kang 
and Brady 2013).         
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Figure 10. Derivatives of known natural products identified in homology-based metagenomic screening: Three 
eDNA-derived sulfotransferases were used to produce mono-, di- and trisulfated glycopeptide congeners from 
teicoplanin aglycone.  An antharcycline analogue with high activity against cancer cells was isolated in a similar 
study.   
 
1.3. Future of metagenomic mining 
Recent development in a range of experimental techniques has made possible the identification, 
isolation and cloning for novel biosynthetic genes at a reasonable pace. Metagenomics is one 
such approach for engendering novel genes. The efforts described in this chapter clearly 
demonstrate the potential of uncultured bacteria as a rich source of biologically active novel 
small molecules and metagenomics as means for accessing such molecules from uncultured 
microbes from essentially any environment. The foundation of all metagenomic approaches is 
the isolation and subsequent examination of DNA extracted directly from naturally occurring 
microbial populations, which avoids the difficulties associated with culturing environmental 
bacteria. The contributions made by metagenomics to the already existing reservoir of 
prokaryotic genes are quite impressive. However, metagenomics is still in its infancy in terms of 
technical development. Advances in heterologous gene expression, library construction, vector 
design and screening techniques will lead to further improvement towards a robust approach for 



















































results discussed in the current doctoral thesis begin to explore these areas in an endeavor to 




















Target Identification of eDNA-Encoded Antibiotics Fasamycins A and B 
 
2.1 Introduction 
The potential clinical utility of any antibiotic can only be augmented by efforts to gain more 
information about their mechanisms of action. A significant increase in bacterial resistance has 
recently overcome almost every class of antimicrobials in clinical use (Levy and Marshall 2004). 
Methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus 
(VRE) are two of the most widely spread antibiotic-resistant organisms that cause nosocomial 
infections. Rates of resistance among these organisms have increased considerably in the past 
decade. About 30% of Enterococcal and 70% of S. aureus infections are reported to be resistant 
to common antibiotics (Moran et al. 2006, Klein et al. 2007). New antibiotics with novel targets 
are needed to combat these common drug resistant phenotypes. Discovery of novel antibiotics 
and elucidation of their molecular targets is therefore key to success in our battle against multi-
drug resistant microorganisms.  
One approach for determining the mode of action of a small molecule involves the selection and 
full genome sequencing of mutants that acquire compound resistance (O’Neill and Chopra 
2004). The current chapter describes our efforts to decipher the mode of action of the novel Type 
II PKS derived antibiotics Fasamycins A (1) and B (2) employing this strategy (Figure 11). 
These two antibiotics were initially identified in a metagenomic homology-based screening 
endeavor through heterologous expression of Type II (iterative, aromatic) polyketide (PK) 
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biosynthetic gene clusters cloned directly from soil samples. These metabolites show activity 
against methicillin-resistant S. aureus and vancomycin-resistant E. faecalis (Feng, Kallifidas et 
al. 2011) (Figure 11) .  
 
Fasamycins bear close structural resemblance to KB-3346-5 substances reported in patent 
literature (Satoshi et al. 2009).  However, there is no report on the mode of action of the 
fasamycins or that of the KB-3346-5 substances. In the current study, we generated multiple 
fasamycin mutant strains and sequenced their genomes. Each strain contained mutations in the 
FabT gene of Type II fatty acid synthase (FASII) cluster. FabT is a transcriptional repressor that 
regulates expression of FASII genes in E. faecalis. Disruption of FabT is predicted to augment 
the expression of this gene cluster. We therefore employed the constitutive overexpression 
strategy to find out which gene from the FASII is responsible for the antibiotic activity of the 
fasamycins. Subsequent in vitro biochemical assays confirmed the identification FabF as the in 
vivo target of the fasamycins. 
                   
2.2 Results 









Fasamycin A (1), R = H
Fasamycin B (2), R = Cl
MIC (µg/ml)        Fasamycin
against                 A          B
E. faecalis            0.8      6.25
(VRE)
S. aureus            3.1      6.25
(MRSA)
Figure 11. Antibiotics Fasamycins A (1) and B (2) were identified through the 
heterologous expression of type II polyketide gene cluster cloned directly from soil 
samples. Fasamycins showed activity against methicillin-resistant Staphylococcus aureus 
and vancomycinresistant Enterococcus faecalis (Feng, Kallifidas et al. 2011)‏ 
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biosynthetic gene cluster (Feng, Kallifidas et al. 2011). Both metabolites demonstrate Gram-
positive specific antibiotic activity (Table 1).  
                       
Monohalogenated Fasamycin A consistently showed higher activity than its dihalogenated 
counterpart, Fasamycin B against the Gram-positive bacteria that were examined (Table 1). 
Although the fasamycins are inactive against wild-type Gram-negative bacteria, they still exhibit 
activity against membrane permeabilized E. coli  (BAS849). This data suggests that the lack of 
antibiotic activity of fasamycins towards Gram-negative bacteria is most likely due to their 
inability to access the right target. Neither metabolite showed cytotoxicity against yeast even at 
the highest concentrations tested. 
 
Investigation of antibiotic resistance strains can provide useful insights into the mode of action of 
the particular antibiotic. To decipher the mechanistic principles of the fasamycins, a resistance 
Table 1. Biological Activity of Fasamycins A (1) and B (2) 
         Organism       1a   2 
Gram-positive bacteria 
Bacillus subtilus BR151      3.1   6.25 
Staphylococcus aureus 6538P     3.1   6.25 
Staphylococcus aureus USA300 (MRSA)   3.1   6.25 
Enterococcus faecalis OG1RF     0.8   6.25 
Enterococcus faecalis EF16 (VRA)    0.8   6.25 
Gram-negative bacteria 
Escherichia coli EC100      >100   >100 
Escherichia coli BAS849     12.5   25 
Ralstonia metallidurans CH34     >100   >100 
Burkholderia thailandensis E264    >100   >100 
Eukaryote 
Saccharomyces cerevisiae w303    >100   >100 
aMinimum inhibitory concentrations are reported as µg/mL. 
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phenotype selection strategy was employed. A single wild-type colony of E. faecalis OG1RF 
was grown to confluence overnight and the resulting culture was plated on LB agar containing 
about 6 times the Minimum Inhibitory Concentration (MIC) for Fasamycin A (5 µg/mL) 
(Bourgogne et al. 2008, Dunny et al. 1978).  For every 108−109 bacterial cells we plated, one 
grew at this elevated Fasamycin A concentration. The advantage of this is that by selecting 
mutants from a natural population of cells instead of from cultures treated with mutagenizing 
agents, the number of mutations per genome is minimized. With only a small number of 
mutations per genome, it should be much easier to establish a functional link between a 
resistance phenotype and the specific mutation leading to this phenotype.  
 
Genomic DNA isolated from nine unique resistant colonies was sequenced using Illumina 
HiSeq2000 technology. The mutant genomes were then compared to E. faecalis OG1RF genome 
and queried for sequence differences (Figure 12). In all cases, the mutations were found in the 
fabT gene of the fasamycin resistant mutant strains. In total, nine mutant strains were sequenced 
and five unique fabT mutations (M1−M5) were found, each of which is predicted to result in 
truncation of the fabT gene product (Figure 13).  
 
These mutations were further confirmed by PCR amplification and re-sequencing of the fabT 
locus from each mutant. The fabT gene is predicted to encode a MarR-like transcriptional 
repressor (Seoane and Levy 1995, Lu et al. 2004).  In E. faecalis, fabT is found in the type II 
fatty acid biosynthesis (FASII) gene cluster (Figure 13) (Schujman and Mendoza, 2008).  
Therefore, if the FabT transcriptional repressor is unable to express functional protein product, it 
will to lead to an increased expression of this fatty acid biosynthesis gene cluster. Based on this 
	 25 
                 
Figure 12. Alignment of fabT mutations with reference genome sequence. Sequencing reads were aligned to the E. 
faecalis OG1RF genome assembly from Baylor University using the Stampy alignment package. Consensus fabT 
gene sequences (M1-M5) observed in fasamycin resistant mutants are shown. Mutations and stop codons are 
highlighted in red. (Adapted from Feng, Chakaraborty et al. 2012) 
WT ATGGAACCTA      ATTTAGAAAC      AGTCAACGAT      TACTTAGTCA      GTGTCTTTAA      TGACATCTTA 
M1 ----------   ----------   ----------    ---------   ---------    --------- 
M2 ATGGAACCTA      ATTTAGAAAC      AGTCAACGAT      TACTTAGTCA      GTGTCTTTAA      TGACATCTTA 
M3 ATGGAACCTA      ATTTAGAAAC      AGTCAACGAT      TACTTAGTCA      GTGTCTTTAA      TGACATCTTA 
M4 ATGGAACCTA      ATTTAGAAAC      AGTCAACGAT      TACTTAGTCA      GTGTCTTTAA      TGACATCTTA 
M5 ATGGAACCTA      ATTTAGAAAC      AGTCAACGAT      TACTTAGTCA      GTGTCTTTAA      TGACATCTTA 
 
WT ACGATTGAAG      AATCTGAATT      GAAAAAATCA      CAATTTAATG      ATTTATCCAT      TACGGAGATG 
M1  ----------   ----------   ----------    ---------   ---------    --------TG 
M2 ACGATTGAAG      AATCTGAATT      GAAAAAATCA      CAATTTAATG      ATTTATCCAT      TACGGAGATG 
M3 ACGATTGAAG      AATCTGAATT      GAAAAAATCA      CAATTTAATG      ATTTATCCAT      TACGGAGATG 
M4 ACGATTGAAT      AATCTGAATT      GAAAAAATCA      CAATTTAATG      ATTTATCCAT      TACGGAGATG 
M5 ACGATTGAAG      AATCTGAATT      GAAAAAATCA      CAATTTAATG      ATTTATCCAT      TACGGAGATG 
 
WT CACACAATCG      AAGCAATTGG      TATGTACAAG      AAAAAAA-CGT      CTTCAGAAGT      AGCCAAGGAA 
M1 CACACAATCG      AAGCAATTGG      TATGTACAAG      AAAAAAA-CGT      CTTCAGAAGT      AGCCAAGGAA 
M2 CACACAATCG      AAGCAATTGG      TATGTACAAG      AAAAAA--CGT       CTTCAGAAGT       AGCCAAGGAA 
M3 CACACAATCG      AAGCAATTGG      TATGTACAAG      AAAAAAA-CGT      CTTCAGAAGT      AGCCAAGGAA 
M4 CACACAATCG      AAGCAATTGG      TATGTACAAG      AAAAAAA-CGT      CTTCAGAAGT      AGCCAAGGAA 
M5 CACACAATCG      AAGCAATTGG      TATGTACAAG      AAAAAAAACGT     CTTCAGAAGT      AGCCAAGGAA 
 
WT CTGTCAATTA      CCGTCGGAAC      ACTTACTGTA      GCGATTAACA      ACTTAGTTAA      AAAAGGCTAT 
M1 CTGTCAATTA      CCGTCGGAAC      ACTTACTGTA      GCGATTAACA      ACTTAGTTAA      AAAAGGCTAT 
M2 CTGTCAATTA      CCGTCGGAAC      ACTTACTGTA      GCGATTAACA      ACTTAGTTAA      AAAAGGCTAT 
M3 CTGTCAATTA      CCGTCGGAAC      ACTTAC-GTA      GCGATTAACA      ACTTAGTTAA      AAAAGGCTAT 
M4 CTGTCAATTA      CCGTCGGAAC      ACTTACTGTA      GCGATTAACA      ACTTAGTTAA      AAAAGGCTAT 
M5 CTGTCAATTA      CCGTCGGAAC      ACTTACTGTA      GCGATTAACA      ACTTAGTTAA      AAAAGGCTAT 
 
WT GTTGAACGTT      TGCGTAGTGA      AGATGATCGA      CGTGTAGTAA      AGCTTGGCTT      AACCAAAAAG 
M1 GTTGAACGTT      TGCGTAGTGA      AGATGATCGA      CGTGTAGTAA      AGCTTGGCTT      AACCAAAAAG 
M2 GTTGAACGTT      TGCGTAGTGA      AGATGATCGA      CGTGTAGTAA      AGCTTGGCTT      AACCAAAAAG 
M3 GTTGAACGTT      TGCGTAGTGA      AGATGATCGA      CGTGTAGTAA      AGCTTGGCTT      AACCAAAAAG 
M4 GTTGAACGTT      TGCGTAGTGA      AGATGATCGA      CGTGTAGTAA      AGCTTGGCTT      AACCAAAAAG 
M5 GTTGAACGTT      TGCGTAGTGA      AGATGATCGA      CGTGTAGTAA      AGCTTGGCTT      AACCAAAAAG 
 
WT GGAAAATTAC      TTTTTAGAGT      CCATCAGCAT      TTTCATCGTG      AAATGGTTAA      AAACATTTTG 
M1 GGAAAATTAC      TTTTTAGAGT      CCATCAGCAT      TTTCATCGTG      AAATGGTTAA      AAACATTTTG 
M2 GGAAAATTAC      TTTTTAGAGT      CCATCAGCAT      TTTCATCGTG      AAATGGTTAA      AAACATTTTG 
M3 GGAAAATTAC      TTTTTAGAGT      CCATCAGCAT      TTTCATCGTG      AAATGGTTAA      AAACATTTTG 
M4 GGAAAATTAC      TTTTTAGAGT      CCATCAGCAT      TTTCATCGTG      AAATGGTTAA      AAACATTTTG 
M5 GGAAAATTAC      TTTTTAGAGT      CCATCAGCAT      TTTCATCGTG      AAATGGTTAA      AAACATTTTG 
 
WT AAAGGCATGG     AGCAAGAAGA    AGAACAAGCG     CTGTTAAGAG     CACTAAAAAA      TCTTCATGAT 
M1 AAAGGCATGG     AGCAAGAAGA    AGAACAAGCG     CTGTTAAGAG     CACTAAAAAA      TCTTCATGAT 
M2 AAAGGCATGG     AGCAAGAAGA    AGAACAAGCG     CTGTTAAGAG     CACTAAAAAA      TCTTCATGAT 
M3 AAAGGCATGG     AGCAAGAAGA    AGAACAAGCG     CTGTTAAGAG     CACTAAAAAA      TCTTCATGAT 
M4 AAAGGCATGG     AGCAAGAAGA    AGAACAAGCG     CTGTTAAGAG     CACTAAAAAA      TCTTCATGAT 
M5 AAAGGCATGG     AGCAAGAAGA    AGAACAAGCG     CTGTTAAGAG     CACTAAAAAA      TCTTCATGAT 
 
WT TTCTTGCAAG      AATACAAATA     A 
M1 TTCTTGCAAG      AATACAAATA     A 
M2 TTCTTGCAAG      AATACAAATA     A 
M3 TTCTTGCAAG      AATACAAATA     A 
M4 TTCTTGCAAG      AATACAAATA     A 
M5 TTCTTGCAAG      AATACAAATA     A!
	 26 
observation, we hypothesized that if the primary in vivo antibacterial target of the fasamycins is a 
FASII biosynthetic enzyme, constitutive overexpression of the FASII gene cluster could lead to 
an increased MIC for Fasamycin A.  
 
 
To test our hypothesis, the fasamycins were tested in an in vitro fatty acid elongation assay. This 
assay employed crude FASII extract that contains all of the enzymes required for fatty acid 
elongation, long-chain acyl CoA (lauroyl-CoA) starter units, and [14C]-malonyl CoA that 
together are used to extend fatty acids on purified holo-ACP substrates. ACP-linked long-chain 
fatty acids are then captured using a phospholipid Flashplate, and 14C incorporation into newly 
generated fatty acids is read by a scintillation counter. In elongation assays with S. aureus FASII 
extract and recombinant S. aureus 6-His-ACP (6 His-SA-ACP), Fasamycins A and B both 
inhibit fatty acid elongation (IC50 = 50 and 80 µg/mL, respectively) and show inhibition curves 
Figure 13. Genomic DNA from nine unique resistant strains were isolated and sequenced. Nine sequenced mutant strains 
contained five different mutations. All mutations were in the fabT gene and are predicted to result in truncated gene 
product. FabT is a transcriptional repressor that regulates the expression of the FASII gene cluster in E. faecalis. The five 
unique fabT mutations (M1−M5) that we observed are shown. (Adapted from Feng, Chakraborty et al. 2012) 
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similar to those of other known FASII inhibitors, BABX and Cerulinn (Figure 14).  
 
                                  
 
Figure 14. Activity of the Fasamycins A and B was tested in an in vitro fatty acid elongation assay. Crude FASII 
extract from S. aureus and recombinant S. aureus 6-His-ACP (6-His-SA-ACP) were used. Both Fasamycins A and 
B inhibit fatty acid elongation (IC50 = 50 and 80 µg/mL, respectively) and show inhibition curves similar to those of 
other known FASII inhibitors. Reactions were run with an excess of [14C]-malonyl-CoA and lauroyl-CoA. 
Elongation assays were run in duplicate. (Adapted from Feng, Chakraborty et al. 2012) 
 
Based on their ability to inhibit FASII elongation pathway in in vitro assay, only five FASII 






              
 
Figure 15. Schematic of FASII biosynthesis. Based on the data obtained from the in vitro FASII elongation assay, 
only five FASII enzymes, FabD, F, G, K, and Z, appear to be potential candidates as fasamycins’ target. 
  
To distinguish the inhibition of FabD or FabF from the reductive enzymes of the elongation 
cycle (FabG, Z, and K), FASII elongation assays were subjected to urea polyacrylamide gel 
electrophoresis. With urea gels it is possible to resolve malonyl-ACP, the product of FabD, from 
the longer chain acyl-ACPs generated in the FASII elongation cycle. It is apparent in Figure 16 
that Fasamycin A does not inhibit FabD-dependent formation of malonyl-ACP (Figure 16, upper 
band) but does inhibit the formation of long-chain acyl-ACPs from the FabD product (Figure 16, 
















































                                   
 
Figure 16. In vitro fatty acid elongation assays use a long-chain acyl CoA starter and the incorporation of [14C]-
malonyl-CoA to measure FASII activity. The reactions were run using lauroyl-CoA, recombinant 6His-SA-ACP, 
and crude S. aureus FASII extracts. Fasamycin A inhibits fatty acid elongation but does not inhibit FabD-dependent 
formation of malonyl-ACP. Reactions were run on a 16% polyacrylamide gel containing 4 M urea to resolve 14C-
labeled malonyl-ACP (upper band) from 14C-labeled long-chain ACPs (lower bands). Lane 1, control reaction 
without lauroyl-CoA; lane 2, complete reaction; lane 3, 200 µg/mL fasamycin A; lane 4, 200 µg/mL BABX. 
(Adapted from Feng, Chakraborty et al. 2012) 
 
The absence of any labeled long-chain acyl-ACPs in the Fasamycin A-containing reaction 
indicates that Fasamycin A inhibits FabF, the initial condensation step of the elongation cycle, 
and not simply a reductive step (FabG, K, and Z) in this cycle. FabF is one of two FASII-specific 
condensation enzymes. It is specifically used in the fatty acid chain elongation cycle, while the 
second condensing enzyme, FabH, is used in fatty acid initiation (Figure 15). Our biochemical 
studies do not rule out the possibility that the fasamycins might also inhibit FabH.  
 
Both gene knockdown and overexpression strategies have been used to identify the protein 
targets of other FASII inhibitors (Wang et al. 2007). For this study, candidate gene 
overexpression was used to further confirm the specific target of fasamycins. In this strategy, 
each FASII gene was individually cloned, overexpressed and assayed for the ability to confer 
Fasamycin A resistance to E. faecalis. FASII genes were PCR-amplified from wild-type E. 
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faecalis genomic DNA and cloned into the E. coli−E. faecalis shuttle expression vector, 
pMGS100 (Fujimoto and Ike, 2001).  Individual FASII gene expression constructs were then 
checked for the ability to confer Fasamycin A tolerance to wild-type E. faecalis. As would be 
expected for a FabF specific antibiotic, only E. faecalis transformed with the FabF 










Figure 17. a) Candidate gene over expression assay. Individual FASII gene expression constructs were examined 
for the ability to confer Fasamycin A tolerance to wild-type E. faecalis. Only E. faecalis transformed with the FabF 
overexpression construct grew robustly in the presence of lethal concentrations of Fasamycin A. A FabT knockout 
mutant with the M1 mutation and wild-type E. faecalis transformed with either a vector control or individual FASII 
overexpression constructs were inoculated onto LB agar containing 5 µg/mL Fasamycin A. b) The MIC ratios for 
antibiotics measured against wild-type E. faecalis and E. faecalis transformed with either the fabF or fabH 
overexpression constructs are listed. (Adapted from Feng, Chakraborty et al. 2012) 
 
To further corroborate our results, we used Cerulenin, a well-characterized FabF inhibitor as a 
control. Cerulenin showed a similar MIC profile against these same FASII overexpression 
strains, while antibiotics with different protein targets did not exhibit elevated MICs against 
FASII overexpression strains (Figure 17b). 
a	
                                              MIC ratio
                                 FabF/WT         FabH/WT
Fasamycin A                 2.5                   1
Fasamycin B                2.0                    1
Cerulenin                     2.0                    1
Tetracycline                  1                       1
Erythromycin                1                       1
Ampicilin                      1                       1




Figure 18. The gem-dimethyl-anthracenone substructure that is common to both the fasamycins and BABX appears 
to represent a natural FabF-specific antibacterial pharmacophore. 
 
The fasamycins and BABX (3) share a chloro-gem-dimethyl-anthracenone substructure (Figure 
18). BABX is a know FabF inhibitor (Kodali et al. 2005, Herath et al. 2005). BABX and 
Fasamycin A also show very similar in vitro FASII and FabF inhibitory activities (Figures 14 
and 16). As with Fasamycin A, BABX shows reduced activity against the FabF overexpression 
strain but not against any other FASII gene overexpression strains (Figure 17b).  
 
2.3 Discussion  
 
In most bacteria, fatty acid biosynthesis is catalyzed by a group of highly conserved proteins 
known as Fatty acid synthesis type II (FASII) system enzymes. FASII system enzymes are 
essential for bacterial membrane lipid biosynthesis and represent increasingly promising targets 
for the discovery of antibacterial agents with new mechanisms of action (Zhang et al. 2006, 
Wright and Reynolds 2007).	Compounds that target the bacterial FAS pathway are not toxic 
against humans because of radical differences in bacterial and human protein structures. 
Additionally, FAS is vital to cell physiology and aids in the design of highly effective genus-
specific inhibitors against major pathogens  (Parsons and Rock 2011). Therefore, FAS systems 




















































agents. So far, there have been only a handful of reports regarding FASII inhibitors as 
therapeutic agents. Only two FASII inhibitors, Triclosan and Isoniazid, both of which target the 
enoyl-acyl carrier protein reductase FabI, are used commercially as antibiotics. FabF-specific 
antibiotics like the fasamycins show activity against therapeutically relevant antibiotic resistant 
bacteria. In the case of the fasamycins and BABX, the high convergence to the same 
pharmacophore on at least two separate occasions, suggests this may provide a promising lead 
scaffold for future drug development against resistant strains. Optimizing the chloro-gem-
dimethyl-anthracenone pharmacophore and the variable region could yield additional FabF-
specific antibiotics with increased efficacy and potentially differing spectra of activity. In fact, 
the specific chlorination pattern on the gem–dimethylanthracenone substructure is clearly 
important for the fasamycins’ activity against E. faecalis, as the monohalogenated analogue 1 is 
almost an order of magnitude more active against this pathogen than the dihalogenated derivative 
2. The study presented in this chapter leads us to believe that we need to expand upon both 
available and yet unknown scaffolds to identify new FASII inhibitors that may have antibacterial 










2.4 Materials and Methods 
 
2.4.1. Isolation of Fasamycins A (1) and B (2)  
Streptomyces albus transformed with the eDNA-derived cosmid cosAZ154 was grown in ISP4 
medium containing 5% HP-20 resin at 30 °C (200 rpm) for 15 days. The HP-20 resin was 
collected, washed with water, and then soaked with methanol. The methanol eluent was 
fractionated on a silica gel flash-column using a CHCl3:MeOH (0.1% acetic acid) step gradient. 
Compounds 1 and 2 eluted from this column with the 95:5 CHCl3:MeOH fraction. Each 
compound was then purified by reversed-phase (XBridge C18, 10 X 150 mm, 5 µm) HPLC (7 
mL/ min) using a linear gradient from 10:90 H2O:MeOH (containing 0.1% formic acid) to 100% 
MeOH (containing 0.1% formic acid) over 30 min. Fasamycins A and B are produced at 
approximately 0.5 mg/L (Feng, Kallifidas et al. 2011). BABX was purchased from Santa Cruz 
Biotechnology.  
 
2.4.2. Selection of Enterococcus faecalis strains resistant to Fasamycin A  
E. faecalis OG1RF was grown overnight in Lysogeny Broth (LB) (Bertani 2004) at 37 °C, and 
100 µL of the overnight culture was spread on a LB agar plate containing 5 µg/mL Fasamycin A. 
The plate was incubated at 37 °C.  Resistant colonies appeared after 18 h. Nine resistant colonies 
were picked and struck on selection plates, and then cultures of the mutants grown in the absence 
of fasamycin were used for sequencing. Selection and analysis of resistant mutants were 




2.4.3. Genome sequencing and analysis methods 
Library Preparation. Genomic DNA libraries were prepared using Illumina TruSeq library kits 
in accordance with the manufacturer’s protocols. Briefly, genomic DNA was sheared using a 
Covaris S2 ultrasonicator, the resultant dsDNA fragments were end-repaired and A-tailed, and 
indexed adapters were ligated to the end-repaired DNA. PCR was performed for 10 cycles, and 
the libraries were quantitated using an Agilent Bioanalyzer 2100 and a High-Sensitivity DNA 
kit. Indexed adapters were used to allow for the multiplexing of samples at the sequencing stage.  
 
Sequencing and Raw Data Analysis. Samples were sequenced on an Illumina HiSeq2000 for 101 
cycles, with an additional 7 cycles for the indexing read. Sequencing was performed according to 
manufacturer’s protocols using TruSeq chemistry. Image data were analyzed in real time by the 
onboard RTA software package. Bcl files produced by RTA were converted to qseq files by 
Illumina’s OLB1 (Satoshi et al. 2009). Software package, and the qseq files were then converted 
to a fastq file for subsequent analysis.  
 
Alignments and Variant Detection. Sequencing reads were aligned to the E. faecalis OG1RF 
genome assembly from Baylor University using the Stampy alignment package. The BWA 
aligner within Stampy was used to decrease processing time (Bourgogne et al. 2008, Albers et al. 
2011). BWA and Stampy allow for gapped alignment to facilitate the alignment of sequencing 
reads in situations where there is significant heterogeneity due to sequence insertions, deletions, 
or other lesions with regard to the reference genome. The alignment files were processed by 
Dindel and the Samtools mpileup program to yield potential variant calls consisting of single 
nucleotide polymorphisms, insertions, and deletions (Lunter and Goodson, 2011, Li et al. 2009).  
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Confirmation of fabT Mutations. Sanger sequencing of fabT genes PCR amplified from resistant 
strains was used to verify each fabT mutation detected in the Illumina sequencing experiment 
(Supporting Information). Colony PCR was performed using whole cells, fabT flanking primers 
(fabTF TGCTTATTTACGATATAGTTTGTGCTTATTTACGATATAGTTTG, fabTR 
TGAAGATTTTTTAGTGCTC), Phusion High-Fidelity DNA polymerase (New England 
Biolabs), and the following cycling parameters: denaturation (98 °C, 2 min), 10 touchdown 
cycles (98 °C, 20 s; 55 °C (dt −1 °C/cycle), 30 s; 72 °C, 30 s), 30 standard cycles (98 °C, 20 s; 
45 °C, 30 s; 72 °C, 30 s), and a final extension step (72 °C, 7 min). Gel-purified amplicons were 
sequenced from both ends using the PCR primers.  
 
2.4.4. Cloning FASII genes from E. faecalis OG1RF 
Each individual gene in the FASII gene cluster of E. faecalis was amplified by PCR using E. 
faecalis OG1RF genomic DNA as a template and Phusion High-Fidelity DNA polymerase. The 
primers used are listed in Table 2. PCR amplicons of the correct size were double-digested with 
EagI (or NotI) and NruI (or ScaI) and ligated with the pMGS100 E. faecalis expression vector 
that had also been double-digested with EagI and NruI (Fujimoto and Ike 2001). Each of the 
constructs was transferred into E. faecalis by electroporation transformation (Fujimoto, et al., 
1991). 
 
2.4.5. Bioactivity: Growth on elevated concentrations of Fasamycin A 
Each E. faecalis strains harboring individual FASII biosynthetic gene expression construct was 
grown overnight at 37 °C in LB containing 12.5 µg/ mL of chloramphenicol. Overnight cultures 
were diluted 104-fold and 5 µL aliquots of each diluted culture were then inoculated onto a LB 
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agar plate containing 12.5 µg/mL of chloramphenicol and 5 µg/mL of fasamycin A. Plates were 
incubated at 37 °C for 18 h, and examined for spots of growth or no growth. Wild-type E. 
faecalis OG1RF transformed with the empty pMGS100 expression vector was used as a negative 
control. Positive control was a strain containing the M1 mutation, transformed with the empty 
pMGS100 expression vector.  
 
2.4.6. Bioactivity: Ex vivo studies 
In these studies, E. faecalis strains harboring FASII gene expression constructs were examined 
for resistance to Fasamycin A as well as other antibiotics. Wild-type E. faecalis transformed with 
empty pMGS100 was used as control. Overnight cultures grown in LB with 12.5 µg/mL 
chloramphenicol were diluted 106-fold. 50 µL aliquot of the dilute cultures were added to each 
well of a 96-well microtiter plate. Fasamycin A and other compounds were dissolved in 
methanol at 5 mg/mL concentration and diluted 100-fold with LB medium. 150 µL of this 
solution was added to the first well of the microtiter plate and then serially diluted across the 
plate. The plates were incubated at 30 °C for 24−48 h. The lowest concentration at which no 
bacterial growth was observed after 24 h are reported as minimum inhibitory concentrations 
(MICs). MICs against other microorganisms were determined in the same manner. Yeast extract 
-peptone-dextrose (YPD) broth was used as media to conduct MIC studies for yeast.  
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2.4.7. Bioactivity: In Vitro studies 
Acyl Carrier Protein (ACP) Cloning. In order to clone Acyl Carrier Protein (ACP), the ACP 
gene from S. aureus was amplified from S. aureus genomic DNA using the following primers 
and PCR conditions. Primers: forward StaphACPFHis, 
GCGCGGATCCGATGGAAAATTTCGATAAAGTAA; reverse StaphACPR, 
GCGCAAGCTTATTTTTCAAGACTGTTAATA (restriction sites added for cloning are shown 
   Name      Sequencea 
FabH_For   GCGCCGGCCGATGAAGAATTATGCACGAATT 
FabH_Rev   GCGCAGTACTTTTTACAGCGTTAGGAGCAG 
acpP_For   GCGCCGGCCGATGGTATTTGAAAAAATTCAA 
acpP_Rev   GCGCTCGCGACAGCCCCCTATTTTCATGTAT 
FabK_For   GCGCCGGCCGATGAAGTGTACTTATCTTAGA 
FabK_Rev   GCGCTCGCGATCACTTAGCCCCAACGCTGAT 
FabD_For   GCGCCGGCCGATGAGGTGTCGTATGAAAACA 
FabD_Rev   GCGCTCGCGACCATTTTTTACCTCCCAGTAAG 
FabG_For   GCGCCGGCCGATGGAATTAACAGGGAAAAACG 
FabG_Rev   GCGCTCGCGACCTTTCGTTTATCCGTGCATG 
FabF_For   GCGCCGGCCGATGAATCGAGTAGTTATTACCGG 
FabF_Rev   GCGCTCGCGAACTGCATGTTAATCCTCCCAG 
accB_For   GCGCCGGCCGATGCAGTTAGAAGAAGTAAAAGC 
accB_Rev   GCGCTCGCGAGTTAATTTCATGTTTTATTCTCC 
FabZ_For   GCGCCGGCCGATGAAATTAACAATTACAGAAATTC 
FabZ_Rev   GCGCAGTACTCGAAAACATTTTTCACCTATCC 
accC_For   GCGCGCGGCCGCATGTTTTCGAAAGTATTAATCGC 
accC_Rev   GCGCAGTACTCTTGCGGCGTTCTTTCTTTAATG 
accD_For   GCGCGCGGCCGCATGGCATTATTTAAAAAGAAA 
accD_Rev   GCGCTCGCGATTAGCGCCACCCTTCCAA 
accA_For   GCGCCGGCCGATGGAAAAGAAAACAGCCAATGA 
accA_Rev   GCGCTCGCGAGAGTAGTAACTTCTAATATTTGCG 
aRestriction sites added to each primer are underlined. 
Table 2. Primers Used for Cloning E. faecalis FASII Genes 
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in bold). Cycling parameters: denaturation (98 °C, 2 min), 35 cycles (98 °C, 20 s; 55 °C, 30 s; 72 
°C, 30 s), and a final extension step (72 °C, 7 min). 50 µL reaction conditions: 10 µL of 5X 
Phusion HF buffer, 1.5 µL of DMSO, 0.3 µL of each 100 mM oligonucleotide primer, 1 µL of 10 
mM dNTPs mix, 1 unit of Phusion High-Fidelity DNA polymerase and water as needed. 
Amplicons were doubly digested with BamHI/HindIII, ligated into BamHI/HindIII digested 
pColaDuet-1 (Novagen), and then transformed into E. coli BAP1 cells to yield pColaDuet: 6His-
SA-ACP. BAP1 is a BL21(DE3)-derived expression strain that contains an inducible 
phosphopantethienyl transferase (sfp gene), which should assist with generating the desired holo- 
ACP (Pfeifer, et al., 2001). Cloning was performed by Dr. Z. Zheng. 
 
Expression and Purification of 6His-SA-ACP. 1 L LB media was inoculated with overnight 
culture of BAP1/pColaDuet:6His-SA-ACP (1:1000 dilution). It was then grown at 37 °C to an 
OD600 of 0.6. The incubation temperature was then reduced to 20 °C, and after 1 h, IPTG (0.5 
mM) was added to induce protein expression. After an additional 16 h at 20 °C, the cells were 
collected by centrifugation (3200g, 15 min). The cell-pellet was resuspended in 40 mL of lysis 
buffer (50 mM Tris, pH 7.5, 0.3 M NaCl, 10 mM imidazole), and the cells were lysed by 
sonication. Crude cell lysates were centrifuged at 25000g for 30 min and the supernatant was 
incubated at 4 °C for 15 min with 1 mL of Ni-NTA resin (Qiagen). This mixture was washed 
with 20 mL of lysis buffer and then 20 mL of lysis buffer containing 50 mM imidazole. 6His-
SA-ACP was subsequently eluted with 5 mL of lysis buffer containing 125 mM imidazole. 6His-
SA-ACP was further purified by anion-exchange chromatography (Mono Q 10/100 GL) using a 
linear gradient from 0.1 M NaCl (10 mM Tris, pH 7.5) to 1 M NaCl (10 mM Tris, pH 7.5) over 
120 min. Protein concentrations were determined with the Bradford assay. Aliquots of protein 
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were flash-frozen in liquid nitrogen and stored at −80 °C.  
 
FASII Enzyme Extract from S. aureus. For the preparation of FASII enzymes (Kodali et al., 
2005) 6 L of S. aureus was grown in LB media at 37 °C until to stationary phase is reached. 
Cells were then harvested by centrifugation (2500g, 10 min, 4 °C) and the cell pellet washed 
twice with ice-cold FASII buffer (0.1 M sodium phosphate, pH 7, 1 mM EDTA, 5 mM β-
mercaptoethanol). The pellet resuspended in 0.5 L of the same buffer and lysed using a French 
press. Cell debris was separated by centrifugation (20000 rpm, 15 min, 4 °C) and the supernatant 
was collected. In order to precipitate the protein, ammonium sulfate was slowly added to the 
supernatant to reach 45% saturation. Precipitated protein was removed by centrifugation (10000 
rpm, 5 min, 4 °C), and ammonium sulfate was slowly added to the supernatant to reach 80% 
saturation. Precipitated protein was collected by centrifugation (10000 rpm, 5 min, 4 °C). The 
resulting pellet was resuspended in 20 mL of FASII buffer and dialyzed (10 kDa MW cutoff) at 
4 °C. Buffer was changed four times during the process. This crude extract from S. aureus 
should contain all the factors necessary for reconstituting the FASII elongation process in vitro. 
Protein concentration measurements were done using the Bradford assay. Aliquots of protein 
were stored at −80 °C after flash freezing in liquid nitrogen. 
 
FASII Elongation Assay. 96-well phospholipid Flashplates (Perkin-Elmer) were used to perform 
FASII inhibition assays (Kodali et al., 2005). The buffer used in this assay was composed of 100 
mM sodium phosphate (pH 7), 5 mM EDTA, 1 mM NADPH, 1 mM NADH, 150 µm DTT, 5 
mM β-mercaptoethanol, 20 µM lauroyl-CoA, 4% Me2SO, and 5 µM DTT pretreated 6xHis-SA-
ACP. 0.4 µg of the FASII protein extract was added to 40 µL of this buffer and incubated with 
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inhibitor at room temperature for 20 min. Elongation reactions were initiated with the addition of 
8 µL of C-2 labeled [14C]-malonyl-CoA (Perkin-Elmer 57.5 mCi/mmol) dissolved in water to a 
final concentration of 4 µM. After 60 min at 37 °C, reactions were quenched by adding 80 µL of 
14% perchloric acid. The 96-well phospholipid Flashplates were then sealed and incubated at 
room temperature overnight. The reactions were assessed using a TopCount scintillation counter 
(Trilux Microbeta).  
 
FASII Elongation and ACP Loading Assay. For this assay, 0.2 µg of FASII extract was added to 
50 µL of the buffer mentioned above and reactions were run in microcentrifuge tubes. After a 
preincubation with inhibitor at room temperature for 20 min, fatty acid elongation was initiated 
by adding a 10 µL aliquot of C-2 labeled [14C]-malonyl-CoA (Perkin-Elmer 57.5 mCi/mmol, 
final concentration 4 µM). After 30 min of incubation at 37 °C, 15 µL of native sample buffer 
was added to each reaction. 16% polyacrylamide gels containing 4 M urea were used to resolve 
the reaction mixtures. Gels were blotted on to polyvinylidene difluoride membranes (Bio-Rad) 















Homology-Based Metagenomic Screening Efforts towards the Identification of 
Novel Type II Polyketide Synthase Gene Clusters 
	
3.1 Introduction 
Given the clinical and commercial success of a diverse collection of aromatic compounds that 
arise from iterative type II polyketide synthases, considerable interest has developed to gain 
access to these microbial secondary metabolites (O’Hagan 1991). The traditional protocol used 
to isolate and identify natural products from bacteria is to first culture an individual bacterium 
from the environment, extract bacterial cultures using organic solvents, and isolate pure 
compounds through activity guided fractionation. However, as mentioned earlier, the difficulties 
associated with culturing environmental bacteria prevent traditional culture-dependent methods 
from being applied to a significant fraction of the bacterial species found in nature. On the other 
hand, culture-independent metagenomic strategies involve direct cloning of DNA from 
environmental samples, which contain the genes encoding for small molecule, bypassing the 
need for isolation and culture of new bacterial species. PCR based studies as well as shotgun-
sequencing efforts indicate that eDNA samples are rich in unique minimal PKS genes (Seow et 
al. 1997, Wawrik et al. 2007, Pang et al. 2008). 
 
These types of culture-independent techniques are the basis of the work described in this chapter. 
There have been multiple reports in the literature describing the identification of type II PKS 
genes from eDNA samples. King, Brady et al. expressed a pathway encoding the biosynthesis of 
a type II polyketide and characterized a new molecule, erdacin (King et al. 2009) with previously 
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unknown pentacyclic skeleton, lending credence to the idea that metagenomics could be 
successfully implemented to tap into the chemical diversity of type II PKS-derived molecules 
from uncultured bacteria. Since this report, several other reports have been published detailing 
the discovery of additional novel type II PKS-derived compounds, such as bioactive pentangular 
polyphenols, calixanthomycin A, arenimycins C-D, arixanthomycins A-C (Kang and Brady 
2014, Kang and Brady 2013), fasamycins (Feng, Kallifidas et al. 2011; Feng, Chakraborty et al. 
2012), fluostatin F (Feng, Kim et al. 2010), and MRSA-active antibiotic tetarimycin A 
(Kallifidas, Kang et al. 2012) to mention a few. Taken together, all these reports offer a glimpse 
of the previously unseen chemistry of the type II PKS derived natural products that metagenomic 
screening has the potential to uncover.  
Aromatic polyketide synthases (type II PKSs) are a family of multienzyme systems that catalyze 
the biosynthesis of a structurally diverse and pharmaceutically important class of natural 
products known as aromatic type II polyketides (Hopwood, 1997). Many of these molecules 
exhibit anticancer (e.g. doxorubicin), antibacterial (e.g. oxytetracycline), antifungal (e.g. 
pradimicin), antiviral (e.g. A-74528) and other related medicinally important activities (O'Hagan, 
1991). These molecules are synthesized, in part, by multifunctional polyketide synthases (PKSs), 
which catalyze repeated decarboxylative condensations between acyl thioesters (acetyl, 
propionyl, malonyl, methylmalonyl, etc.). Type II PKS systems comprise of aggregates of small 
polypeptides, each having a single catalytic activity that is used iteratively during the 
biosynthesis. All type II PKS gene clusters encode a “minimal PKS” consisting of three 
functionally discrete proteins: a ketosynthase (KSα), chain length factor (KSβ), and acyl carrier 
protein (ACP). This core of three enzymes is responsible for the construction of the polyketide 
backbone through iterative condensation of multiple acyl-CoA units (Figure 19). Additional PKS 
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subunits, ketoreductases, cyclases and aromatases determine the folding pattern of the nascent 
poly-β-keto intermediate and a set of tailoring enzymes, such as oxygenase, glycosyltransferase, 
etc. further functionalize the aromatic polyphenols to create the final polyketide natural products 





Figure 19. Iterative use of the minimal PKS for the assembly of aromatic type II polyketide backbone. Minimal 
PKS composed of three proteins: ketosynthase alpha (KSα), ketosynthase beta/chain length factor (KSβ), and acyl 
carrier protein, ACP. The minimal PKS is responsible for the iterative condensation of malonyl CoAs into a nascent 
polyketide chain that is then cyclized, aromatized, reduced, oxidized, rearranged, and functionalized in pathway-
specific ways to generate structural diversity that is known to arise from type II PKS systems 
 
The cloning and analysis of DNA extracted directly from environmental samples (environmental 
DNA, eDNA) provides a means of exploring the biosynthetic capacity of natural bacterial 
populations. eDNA libraries are essentially large reservoirs of bacterial genetic diversity from 
which new secondary metabolite gene clusters can be systematically recovered and studied. In 
this chapter, I describe my efforts to gain access to the chemical diversity of the aromatic natural 
products synthesized by bacterial type II polyketide synthases (PKSs) through metagenomic 
approaches. Through homology-based screening of a large metagenomic library, I identified, for 
the first time, the gene cluster for the biosynthesis of the known Type II PKS derived 



















3.2.1 Screening for Type II PKS pathways	 
In our attempt to identify novel type II polyketide natural products, a multimillion membered 
metagenomic library constructed using sample collected from Texas was screened. The 
biosynthetic gene-clusters of these natural products contain, among other genes, a set of three 
highly conserved genes, a ketosynthase (KSα), a chain 
length factor (CLF or KSβ) and an acyl carrier protein 
(ACP) (Figure 19, 20). For the present work, I used a set 
of degenerate primers targeting conserved regions on the 
conserved KSα gene to perform homology-based screening 
of the environmental DNA (eDNA) library. It has been shown previously that KSα genes group 
into clades that correlate well with the chain length and initial cyclization pattern of the 
polyketide precursor produced by a gene cluster (Wawrik et al. 2005). KSα genes can therefore 
be used as bioinformatics markers for predicting both the length of the polyketide chain produced 
by a minimal PKS and the initial polyketide cyclization pattern of the polyketide chain. The 
primers (dp:540F and dp:1100R, Figure 20) were designed to amplify ~550 bp long DNA 
sequence from the Texas (Tx) library (Figure 21). In order to characterize the amplicons, BLAST 
search was performed on individual sequences, followed by a ClustalW-based phylogenetic 
analysis comparing the eDNA derived KSα sequences to those from functionally characterized or 
known type II PKS clusters. It’s been found that type II PKS clusters with KSα gene sharing 
>85% identity, tend to encode for molecules with very similar chemical structures (Reddy et al. 
2012). Clustering KSα sequences at 85% identity revealed 91 unique sequences from the Tx 
library (Figure 22, 23). A summary of the results of the screen is presented in Figure 21.	 
      
dp:540F dp:1100R 
KSα" CLF ACP 
Figure 20. eDNA derived PKS probes: 
Unique KSα genes were used as probes to 
recover type II PKS containing clones from 








                      Figure 21. An overview of TX library screening results.  
 
3.2.2 Recovery, retrofitting and heterologous expression of eDNA-derived Type II PKS pathways 
Based on the above analyses, forty clones carrying unique KSα sequences were picked for 
recovery. In order to recover the clones from eDNA library, the unique KSα sequences were used 
as probes. A second set of specific primers was designed based on the particular amplicon 
sequence of that KSα gene obtained during our initial screening. The type II PKS cosmid clones 
of interest were then recovered from library using successive rounds of serial dilution and PCR 
screening. In total thirty type II PKS gene containing clones were recovered and carried forward 
for functional analysis (Figure 21, 22). 
Although, the metagenomic libraries are constructed in E. coli, it is not a desirable host for 
heterologous expression of small molecules. Instead Streptomyces albus was chosen as the 
heterologous host for our expression studies. The predominantly soil dwelling gram-positive 
Streptomyces sp. is well known for secondary metabolite production and is the source for about 
two-thirds of clinically useful antibiotic natural products (Kieser, Bibb et al. 2000). Streptomyces 
sp. has extensive precedent as a successful heterologous host (Pfeifer and Khosla 2001). 
Furthermore, nearly all of the identified KSα genes in this work have closest homology with KSα 
genes from Streptomyces sp.  
Figure 2. An overview of Texas library screening results 
Texas Library (107) 450 hits
Homology 




























Method: Neighbor Joining; Best Tree; tie breaking = Systematic






























































































Figure 22. A ClustalW-based phylogenetic tree of the eDNA-
derived KSa genes is shown. Thirty clones (underlined) were 
selected randomly for recovery. The tree was constructed using 













Figure 23. Comparion of the cosTX451 derived KSα 
amplicon sequence with those from sequenced PKS gene 
clusters that encode known type II PKS derived 
secondary metabolites. ClustalW-based phylogenetic tree 
was constructed using Neighbor-joining method. Shown 
here is an angucycline carbon skeleton. 
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Streptomyces albus has proved to be an extremely efficient heterologous host because of its 
relatively fast growth rate, ample sporulation and ease of conjugation with E. coli. These factors 
helped facilitate both the conjugation of eDNA-derived Type-II PKS gene cluster into S. albus 
and the characterization of the molecules these pathways encode for. 
Recovered clones from the Tx library containing type II PKS genes were retrofitted so that they 
could be conjugated into S. albus for heterologous expression studies. Recovered cosmids were 
digested with PsiI, which cuts in the cosmid vector but rarely cuts in eDNA inserts. Each 
linearized cosmid was then ligated with the 6.81 kb DraI fragment from pOJ436 (Feng et al. 
2011). This fragment contains an origin of transfer (oriT) and elements of the phiC31 attp-attB 
integration system needed for integration into diverse Streptomyces sp. (Bierman et al. 1992). 
Retrofitted cosmids were transformed into E. coli S17.1 and conjugated into S. albus using 
standard Streptomyces conjugation protocols (Practical Streptomyces Genetics by T. Kieser, M. 
J. Bibb, M. J. Buttner, K. F. Chater, D. A. Hopwood).  
 
Color production, TLC and HPLC-MS analysis were used to identify clone specific metabolite 
production in recombinant Streptomyces harboring PKS pathways. In the present screen, out of 
thirty PKS gene clusters from Tx library examined in this study, one clone, cosTX451, conferred 
the production of clone specific metabolites to S. albus, based on visual inspection, TLC and 
HPLC-MS of crude extracts (Figure 24). A number of clone-specific metabolites were observed 
upon HPLC-MS analyses of the fermentation broth extracts derived from S. albus transformed 
with cosTX451 (Figure 22). A ClustalW-based phylogenetic analysis using KSα genes from the 
eDNA derived clone cosTX451 as well as those from functionally characterized type II gene 
clusters indicated that the pathway cosTX451 was likely to produce angucycline (Rohr et al. 
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1992) family of type II polyketide natural products (Figure 23). The closest homolog to this KSα 
gene is from the hatomarubigin pathway from Streptomyces sp. strain 2238-SVT4  (Hayakawa et 
al. 1991).	 
 






Figure 24. S. albus transformed with eDNA-derived PKS clone cosTX451 was screened for the production of clone 
specific metabolites. a) LC-MS analysis of crude ethyl acetate extract of Streptomyces culture broth showed multiple 
clone-specific peaks (red triangles). Clone-specific metabolite 2 was isolated for characterization. A negative control 
was carried out using S. albus transformed with empty vector. b) Recombinant S. albus on MS agar plates showed 
colored metabolite production for clone cosTX451. Empty vector control did not show strong color phenotype.  
 
3.2.3 Sequencing of PKS containing eDNA-derived clones 
In order to reveal the gene sequence and organization, the eDNA insert in cosTX451 clone has 
been fully sequenced. From the sequencing results, the polyketide biosynthetic pathway appears 
to be only partially captured in this clone. Two overlapping clones, cosTX578 and cosTX2512, 
were identified by rescreening the Tx library using primer pairs designed to recognize both the 
proximal and distal ends of cosTX451. These clones were successfully recovered and sequenced. 
Sequencing data analysis of cosTX578 revealed no relevant biosynthetic genes. Other 
overlapping clone, cosTX2512, however contained additional type II PKS biosynthetic genes 
that could reconstruct the original pathway. The completed sequencing efforts on cosTX451 and 
cosTX2512 revealed ~30 kb biosynthetic gene cluster containing 31 predicted open reading 
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frame (ORFs) (Figure 25). These 31 ORFs include the minimal PKS, ketoreductase, cyclase, and 
aromatase expected in a type II PKS gene cluster. Additionally, a number of post-PKS enzymes, 
regulatory proteins, a transporter and several hypothetical proteins are also encoded for by this 
gene cluster. Phylogenetic comparison of the minimal PKS gene sequences revealed they are 
most closely related to the angucyclines hatomarubigin (Kawasaki et al. 2010) and jadomycin 
(Han et al. 1994) pathways (Figure 23).  
        
        
Figure 25. ORF diagram and gene table for TX451/2512 pathway. ORFs were predicted using MetaGeneMark and 
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3.2.4 Overlapping-clone recovery and transformation-associated recombination (TAR) of eDNA-
derived Type II PKS pathways 
In the present screen, I identified one clone (cosTX451) that conferred the production of clone 
specific metabolites to S. albus. A number of clone-specific metabolites were observed upon 
HPLC-MS analyses of the fermentation broth extracts derived from S. albus transformed with 
cosTX451.  
                           
Figure 26. TAR cloning of two overlapping eDNA clones carrying the type II PKS pathway BAC:TX451/2512. The 
TAR reassembled construct was shuttled into S. albus for heterologous expression experiments. 
 
Full sequencing of the eDNA insert in cosTX451 revealed that the biosynthetic pathway is only 
partially captured in this cosmid. In order to gain access to the complete pathway, one 
overlapping clones, cosTX2512, was identified and recovered by rescreening the Tx library 
using primer pairs designed to recognize both the proximal and distal ends of cosTX451 (Figure 
26). Sequence analysis of cosTX2512 suggested that this clone captures a large part of the 
pathway and the reassembled pathway was likely to produce fully functionalized secondary 
































PKS gene-cluster is novel and had not been reported in literature previously. Therefore, 
cosTX451 was assembled with the overlapping clone cosTX2512 into a complete pathway 
through Transformation Associated Recombination (TAR) in Saccharomyces cerevisiae (Feng, 
Kim et al. 2010; Kim et al. 2010) into a larger bacterial artificial chromosome (BAC) clone 
(Figure 26). The construct BAC:TX451/2512 was confirmed with sequencing and conjugated 
into S. albus for heterologous expression (Figure 26).  
3.2.5 Isolation and structural characterization of eDNA encoded natural products: Seitomycin, 
Rabelomycin, 8-Methylrabelomycin and 1-Deoxo-1-hydroxy-8-O-methylrabelomycin 
To learn more about the molecules encoded by eDNA-derived Type-II PKS gene cluster, the 
major clone specific metabolites of the recombinant S. albus BAC:TX451/2512 clone was 
isolated and structurally characterized. The secondary metabolite profile obtained from 
heterologous expression of the TAR construct (BAC:TX451/2512) was different from what was 
observed for cosTX451 alone (Figure 27). Attempts were made to isolate and structurally 
characterize metabolites from the truncated cosTX451 pathway. However, only one metabolite 
(4) was successfully isolated from this clone. The rest of the compounds appeared to be unstable 
and attempts to isolate them were unsuccessful. Efforts were focused on the isolation and 
structural elucidation of the clone-specific metabolites produced by the fully assembled pathway. 
Cultures of S. albus transformed with BAC:TX451/2512 were grown in R5A media. After 
incubating at 30 °C for 10 days, the cultures were extracted with ethyl acetate. This crude extract 
was partitioned by reversed phase HPLC to isolate the major metabolites. An extensive 1- and 2-
D NMR analysis utilizing 1HNMR, 13CNMR, COSY, HMBC and HMQC were employed to 
deduce a potential structure of the metabolites 1-4.  
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Figure 27. HPLC analysis of crude ethyl acetate extracts of S. albus harboring BAC:TC451/2512 and 
cosTX451clones. The secondary metabolite profile obtained from heterologous expression of the TAR construct 
(BAC:TX451/2512) was different from what was observed for cosTX451 alone. Compounds 1-4 were isolated for 
further analysis.  
 
Characterization of seitomycin (1) 
The 1H NMR spectrum showed the presence of H-bonded OH group at δ 12.3, and two pairs of 
aromatic protons at δ 8.0/7.6 (5-H, 6-H) and 7.64/7.4 (9-H, 10-H) that appeared as doublets with 
coupling constants 8.0 and 9.4 Hz, respectively. In the aliphatic region, two singlets at 3.9 (8-
OCH3) and 1.3 (3-CH3) each for three hydrogens indicated the presence of methoxy and methyl 
groups. Presence of two AB at 2.8 and 3.0 (4-H) and ABX at 2.0 and 1.8 (2-H) signals, was due 
to two methylene groups. A triplet at 5.8 (1-H) suggests the presence of one H attached to an 
























































The 13C NMR spectrum consisted of 20 signals, of which two are carbonyl groups at δ 192 (C-
12) and 181.8 (C-7), twelve aromatic and six aliphatic carbons. Two aromatic carbons at 155.9 
(C-11) and 154 (C-8) and three aliphatic signals at 68.2 (C-3), 64.7 (C-1) and 57.6 (8-OCH3) are 
likely oxygen attached. Given that there are only four aromatic hydrogens, it is rational to say 
that the remaining eight aromatic carbons are quaternary, two of which are oxygen attached. 
Among the aliphatic carbons, two methyl and two methylene groups are present. Existence of a 
methine group carrying a triplet hydrogen at δ 5.8 is highly likely.  
   
In the HMBC spectrum, the first set of ortho-positioned aromatic protons at δ 7.64 and 7.4 
coupled with carbon signals at δ 155.9 (C-11) and 119.1 (C-7a), and at δ 154.0 (C-8) and 118.1 
(C-11a), respectively. The OH signal at δ 12.3 showed couplings to signals at δ 155.9 (C-11), 
Position 1H (δ in ppm) Position 13C (δ in ppm) 
1-H 5.80 (t, J = 6.4 Hz) C-1 64.7 
2-H 1.82 (dd, J = 13.9, 6.1 Hz) C-2 45.9 
2-H 2.05 (ddd, J = 13.9, 6.7, 1.5 Hz) C-3 68.2 
3-CH3 1.32 (s) C-4 45.5 
4-H 2.83 (d, J = 16.9 Hz) C-4a 144.2 
4-H 3.04 (d, J = 17.3 Hz) C-5 136.4 
5-H 7.60 (d, J = 9.4 Hz) C-6 126.4 
6-H 8.0 (d, J = 7.9 Hz) C-6a 135.5 
8-OCH3 3.91 (s) C-7 181.8 
9-H 7.64 (d, J = 8.0 Hz) C-7a 119.1 
10-H 7.41 (d, J = 9.4 Hz) C-8 154.0 
11-OH 12.3 (s) C-9 124.6 












































Figure 28. Structural characterization of Seitomycin (1). a) Chemical structure of Seitomycin with carbon numbering. b) 
Table showing chemical shifts and coupling constants in 1H and 13C NMR spectra. c) COSY and HBMC correlations 




126.8 (C-10) and 118.1 (C-11a), and the methoxy protons correlated with a signal at δ 154.0 (C-
8). Strong 1H-1H COSY correlations were observed between the protons at δ 7.64 and 7.4. In the 
HMQC spectrum, these protons showed connectivity to carbons at 124.6 (C-9) and 126.8 (C-10), 
respectively. Methoxy protons are attached to a carbon at δ 57.6. These combined 1H-1H COSY, 
HMBC and HMQC correlations allowed to construct a p-methoxy-phenol moiety present in 
seitomycin. Similarly, the other pair of aromatic ortho-protons at δ 8.0 and 7.6, respectively, 
showed relevant three-bond couplings with signals at δ 181.8 (C-7), 142.2 (C-4a), 131.6 (C-12a) 
and at δ 142.6 (C-12b), 135.5 (C-6a) and 45.5 (C-4). In addition to having strong 1H-1H COSY 
correlations, these protons at δ 8.0 and 7.6 are connected to carbons at 126.4 and 136.4 as 
revealed by HMQC. This and the COSY, HMBC and HMQC correlations of the aliphatic 
protons revealed the right half of the molecule. Due to the missing couplings of aliphatic ring 
protons with the quinone carbonyls, the position of the methoxy group at C8 or C11 could not be 
directly deduced from the HMBC spectrum. The 13C signal of a chelated carbonyl group in a 
quinone is, however, usually by about Δδ 10 at deeper field as that of the non-chelated carbonyl. 
Since the H6 signal couples in the HMBC spectrum with the non-chelated quinone carbonyl at 
181.8 (C7), the methoxy group must be located at C8 and the phenolic OH group therefore at 
C11, resulting in structure 1 for seitomycin (Abdelfattah et. al. 2003).  
 
Characterization of rabelomycin (2) 
The 1H NMR spectrum showed the presence of two chelated OH groups at δ 11.6 (8-OH) and 
12.3 (6-OH), and four aromatic protons: a singlet at δ 71.5 (5-H), two doublets at δ 7.49 (11-H) 
and 7.35 (9-H) each with coupling constants 8 Hz, and a triplet at δ 7.8 (10-H) with a coupling 
constant of 8 Hz. From the characteristic splitting pattern and the identical coupling constant 
	 55 
values, it appears that the three protons at δ 7.49, 7.35 and 7.8 are in the same aromatic rings.  In 
the aliphatic region, a singlet at δ 1.3 (3-CH3) for three hydrogens indicated the presence of a 
methyl group. Presence of a pair of AB systems at δ 3.0/3.1 (4-H) and 2.68/2.95 (2-H) were due 
to two methylene groups.  
 
 
The 13C NMR spectrum consisted of 19 signals, of which three are carbonyl groups at δ 195.8 
(C-1), 191.0 (C-7) and 183.4 (C-12), twelve aromatic and four aliphatic carbons. Two aromatic 
carbons at 162.3 (C-6) and 160.6 (C-8) and one aliphatic carbon at 71.2 (C-3) are likely attached 
to oxygen. Given that there are only four aromatic hydrogens, it is likely that remaining eight 
aromatic carbons are quaternary, two of which are oxygen attached. Among four aliphatic 
carbons, one methyl and two methylene groups are present.  
Position 1H (δ in ppm) Position 13C (δ in ppm) 
2-H 2.68 (d, J = 15.0 Hz) C-1 195.8 
2-H 2.95 (d, J = 15.0 Hz) C-2 53.2 
3-CH3 1.32 (s) C-3 71.2 
4-H 3.0 (s) C-4 43.6 
4-H 3.1 (s) C-4a 128.7 
5-H 7.15 (s) C-5 135.8 
6-OH 12.28 (s) C-6 162.3 
8-OH 11.64 (s) C-6a 115.5 
9-H 7.35 (d, J = 8.0 Hz) C-7 191.0 
10-H 7.80 (t, J = 8.0 Hz) C-7a 116.7 











































Figure 29. Structural characterization of Rabelomycin (2). a) Chemical structure of Rabelomycin with carbon 
numbering. b) Table showing chemical shifts and coupling constants in 1H and 13C NMR spectra. c) COSY and HBMC 
correlations present in Rabelomycin.  
a) b) 
c) 
A B C 
D 
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In the HMBC spectrum, three aromatic protons at δ 7.35, 7.49 and 7.8 made extensive three-
bond couplings. These protons coupled with carbon signals at δ 116.7 (C-7a) and 121.5 (C-11), 
at δ 183.4 (C-12), 116.7 (C-7a) and 123.6 (C-9), and at δ 137.6 (C-10/11a) and 160.6 (C-8), 
respectively. The OH signal at δ 11.6 showed couplings to carbon signals at δ 116.7 (C-7a) and 
123.6 (C-9). Strong 1H-1H COSY correlations were observed among the three aromatic protons. 
In the HMQC spectrum, these protons showed connectivity to carbons at δ 123.6 (C-9), 121.5 
(C-11) and 137.5 (C-10/11a), respectively. The combined 1H-1H COSY, HMBC and HMQC 
correlations allowed constructing a phenol moiety containing A ring present in rabelomycin.  
 
Similarly, in the HMBC spectrum, the other aromatic proton at δ 7.15 showed relevant three-
bond couplings with signals at δ 115.5 (C-6a), 152.0 (C-12b) and 43.6 (C-4). The OH signal at δ 
12.2 showed correlations with carbons at δ 135.8 (C-5), 115.5 (C-6a) and a two-bond coupling 
with carbon 162.3 (C-6). HMQC revealed that proton at δ 7.15 is connected to carbon at δ 135.8 
(C-5). Extensive COSY, HMBC and HMQC correlations of the aliphatic protons established the 
C and D rings as well as the angular structure of the molecule. Although, there were no 
couplings among the protons in the C and D rings with the quinone carbonyls, the positions of 
the phenolic groups in A and C rings with respect to the quinone carbonyls C-7 and C-12 were 
easily established. Like seitomycin, the 13C signal of a chelated carbonyl group (C-7) in a 
quinone appeared at deeper field by about Δδ 10 compared to that of the non-chelated carbonyl 
(C-12). Since the H11 signal couples in the HMBC spectrum with the non-chelated quinone 
carbonyl at δ 183.4 (C-12), the phenolic group in ring A must be located at C8. The position of 
the phenolic OH group in ring C was placed accordingly, resulting in structure 2 for rabelomycin 
(Liu et. al. 1970). This is also in accordance with the reported structure of rabelomycin. 
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Characterization of 8-O-methylrabelomycin (3) 
Structure of 8-O-methylrabelomycin 3 was determined similarly. The numbers of aromatic and 
aliphatic protons as well the coupling patterns are identical to those present in rabelomycin. 
Obvious differences were the presence of a methoxy group at δ 3.96 (8-OCH3) and the absence 
of phenolic OH at 11.6 with little or no changes in other values in the 1H NMR spectrum.  
 
 
In 13C spectrum, the appearance of a signal at 57.3 (8-OCH3) corroborated with the presence of a 
methoxy group. Such observations indicated that the compound is a C8 methoxy derivative of 
rabelomycin. Further confirmation came from COSY, HMQC and HMBC correlations. Unlike 
rabelomycin, all the HMBC connectivity involving C8 phenolic was absent in the new 
compound. However, hydroxyl proton at δ 12.9 (6-OH) correlated well with carbon signals at δ 
Position 1H (δ in ppm) Position 13C (δ in ppm) 
2-H 2.61 (s) C-1 195.7 
2-H 2.83 (s) C-2 54.1 
3-OH 4.9 (br s) C-3 71.7 
3-CH3 1.3 (s) C-4 44.5 
4-H 2.91 (d, J = 15.0 Hz) C-4a 140.0 
4-H 3.03 (s) C-5 121.8 
5-H 6.8 (s) C-6 162.1 
6-OH 12.9 (s) C-6a 119.6 
8-OCH3 3.96 (s) C-7 187.3 
9-H 7.46 (dd, J = 1.5, 8.0 Hz) C-7a 118.9 
10-H 7.81 (t, J = 8.0 Hz) C-8 160.0 











































Figure 30. Structural characterization of 8-O-methylrabelomycin (3). a) Chemical structure of 8-O-methylrabelomycin 
with carbon numbering. b) Table showing chemical shifts and coupling constants in 1H and 13C NMR spectra. c) COSY 




119.6 (C-6a), 162.1 (C-6) and 121.6 (C-11), thus confirming the presence of methoxy group at 
C8 position. The NMR spectra are identical to those reported for 8-O-methylrabelomycin (Fotso 
et. al. 2008).  
 




The 1H-NMR spectrum of 4 is very similar to that of 8-O-methylrabelomycin, with the major 
difference being the presence in 4 of a broad apparent quartet at δ 5.61 (1-H) and a doublet at δ 
4.8 (1-OH). Presence of these protons each with integration one suggested that one of the 
carbonyls in 8-O-methylrabelomycin has been reduced. The 1H-1H COSY spectrum showed a 
Position 1H (δ in ppm) Position 13C (δ in ppm) 
1-H 5.61 (m) C-1 64.1 
1-OH 4.8 (br. S) C-2 45.9 
2-H 2.13 (dd, J = 14.1, 5.5 Hz) C-3 68.2 
2-H/4-H 2.70 (br. M) C-4 44.5 
3-OH 4.50 (br. S) C-4a 148.4 
3-CH3 1.30 (s) C-5 124.4 
4-H/2-H 2.70 (br m) C-6 160.7 
4-H 2.93 (d, J = 17.0 Hz) C-6a 117.2 
5-H 7.10 (s) C-7 189.0 
6-OH 13.0 (s) C-7a 137.8 
8-OCH3 4.0 9 (s) C-8 161.0 
9-H 7.61 (d, J = 8.4 Hz) C-9 120.2 
10-H 7.91 (d, J = 8.4 Hz) C-10 137.2 













































Figure 31. Structural characterization of 1-Deoxo-1-hydroxy-8-O-methylrabelomycin (4). a) Chemical structure of 1-
Deoxo-1-hydroxy-8-O-methylrabelomycin with carbon numbering. b) Table showing chemical shifts and coupling 





coupling between the methine at δ 5.6 (1-H) and the doublet of doublet methylene protons at δ 
2.13 (2-H) indicating that the C-1 carbonyl has been reduced. The carbon spectrum supported 
this conclusion on the basis of only two carbonyl groups at δ 189.0 (C-7) and 187.0 (C-12) in 4 
and the presence of an additional methine carbon at δ 64.1. HMQC correlation spectra showed 
the connectivity of H-1 to C-1 at δ 64.1. The reduction of the carbonyl at C-1 was further 
confirmed by the HMBC correlation of the H-2 protons to C-1 at δ 64.1. Presence of the other 
long-range couplings as revealed by HMBC remained identical to those present in 8-O-
methylrabelomycin. The spectra are identical to those reported for 1-deoxo-1- hydroxy-8-O-
methylrabelomycin (Fotso et. al. 2008). 
 
3.2.6 Proposed biosynthesis of seitomycin 
The biosynthesis of the type II PKS derived angucycline compound seitomycin can be 
rationalized on the basis of the predicted functions for the genes found within the 
BAC:TX451/2512 clone (Figure 25). The intermediate compounds isolated from this pathway, 
namely 8-O-methylrabelomycin 3 and 1-deoxo-1-hydroxy-8-O-methylrabelomycin 4 further 
support this hypothesis. Type II polyketide synthase (PKS) enzymes utilize a starter unit, most 
commonly, acetyl CoA and extender units (9 malonyl CoA) to establish a decaketide backbone 
(Figure 28). In our proposed biosynthetic scheme for seitomycin, the C20 angucline backbone (I) 
is predicted to be synthesized by enzymes encoded by the minimal PKS genes (6, 7, 8) in the 
cluster. The first ring closure is proposed to take place by the action of minimal PKS genes as 
well (Khosla 2009). The decaketide intermediate then undergoes further cyclization and 
aromatization to establish the tri-cyclic backbone (II) of C20 angucline. A ketoreductase (orf 10), 
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Figure 32. Proposed biosynthetic scheme for Seitomycin (1) based on gene function prediction defined by sequence 
homology and domain analysis. Red color indicates enzyme-mediated transformations. aThe monoxygenase (orf 14, 
homologue of LndE gene from landomycin E biosynthetic cluster) can catalyze oxidation at C-12 and removal of 
oxygen at C-6. bOrf 15 is a bifunctional oxygenase-reductase enzyme and a homologue of LndM2. In this case it is 
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Table 3: List of genes not used in biosynthetic hypothesis of seitomycin 
 
The second and third ring closures take place through the action of cyclase (orf 5) and a 
decarboxylase (orf 12) to produce the well-known intermediate from angucycline pathways, 
UWM6. This intermediate then undergoes spontaneous elimination of one water molecule to 
generate intermediate III (Figure 32). This intermediate is then transformed into tetrangomycin, 
another well-characterized intermediate from angucycline biosynthesis, by a monooxygenase 
(orf 14). This monooxygenase is homologous to LndE enzyme from Landomycin E biosynthetic 
gene cluster and is know to oxygenate at C-12 of angucycline backbone (Kharel et al. 2012). In 
this biosynthetic proposal, intermediate tetrangomycin is predicted to enter into two distinct 
pathways resulting in the formation of differentially hydroxylated angucylines. Hydroxylation at 
C-6 of tetrangomycin (orf 15) yields rabelomycin (2), a common shunt product/intermediate 
from angucycline pathways. Orf 15 represents an oxygenase-reductase family enzyme that is 
homologous with LndM2, which is known to catalyze hydroxylation at C-6 position of 
tetrangomycin to produce rabelomycin (Kharel et al. 2012). Methylation of rabelomycin at C-8 
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hydroxyl group via an O-methyltransferase (orf 19) leads to 8-O-methyrabelomycin (3), which 
through the action of a reductase, most likely orf 17 of our cluster, generates 1-deoxo-1-hydroxy-
8-O-methylrabelomycin (4). Methylation of tetrangomycin at the C-8 hydroxyl group (orf 19) 
followed by the reduction of C-1 carbonyl group (orf 17) and hydroxylation at C-11 by an 
oxidoreductase enzyme (orf 16) could lead to the formation seitomycin (1) (Figure 32).  
 
3.3 Discussion 
Uncultured soil bacteria is a prolific source of chemical diversity that is yet unexplored. eDNA 
libraries constructed using soil samples from different geographical regions could give us access 
to the genetic diversity of these uncultured microbes. To discover a broader range of biosynthetic 
pathways, an expression independent sequence-based strategy was applied to recover cosmids 
containing biosynthetic gene clusters. A number of studies have indicated that eDNA samples 
are rich in Type II PKS genes (Pang et al. 2008; Wawrik, Kutliev et al. 2007). I screened a 
multimillion membered metagenomic library constructed using sample collected from Texas 
using a set of degenerate primers based on the conserved KSα gene from type II PKS cluster as 
probe. Preliminary sequence-based screens demonstrated the successful recovery of biosynthetic 
cosmids encoding a diverse range of type II polyketides. A phylogenetic analysis was carried out 
on the eDNA-derived KSα genes. This analysis confirmed that the Tx eDNA library is rich in 
type II PKS biosynthetic pathways. Clustering KSα sequences at 85% identity revealed 91 
unique clones. Based on the above analysis, thirty clones carrying unique KSα sequences were 
picked at random and were recovered from eDNA library. One clone, cosTX451, was identified 
that conferred the production of clone specific metabolites to S. albus. Full sequencing of the 
eDNA insert in cosTX451 revealed that the biosynthetic pathway is only partially captured in 
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this cosmid. In order to access the complete pathway, one overlapping clone, cosTX2512, was 
identified and recovered by rescreening the Tx library. TX451 was assembled with the 
overlapping clone cosTX2512 into a complete pathway through Transformation Associated 
Recombination (TAR). The secondary metabolite profile obtained from heterologous expression 
of the TAR construct (BAC:TX451/2512) was different from what was observed for cosTX451 
alone. In total, four natural products were isolated and characterized from this pathway.  
 
Extensive NMR studies revealed that the molecules encoded by this gene cluster indeed 
belonged to the angucycline class of type II PKS derived natural products. The angucyclines 
represent the largest group of type II PKS-engineered natural products (Rohr and Thiericke 
1992). Seitomycin, a Type II PKS derived angucycline antibiotic was isolated as the major 
metabolite of this pathway. Although no new metabolites were isolated in this study, using 
metagenomic tools, I successfully identified, for the first time, the biosynthetic gene cluster for 
the Type II PKS derived angucycline antibiotic Seitomycin. The current study provides further 
support to the idea that sequence-based screening of large metagenomic libraries can lead to the 
discovery of biosynthetic machinery for new chemistry. These results, together with those of 
other small-molecule directed metagenomic studies, suggest that large-scale functional screening 
of eDNA derived clones should be a productive strategy for generating structurally previously 






3.4 Materials and Methods 
 
3.4.1 General experimental procedures 
Streptomyces albus J1074 was used for heterologous expression studies. 1H and 2D NMR data 
were obtained on a Bruker Avance-600 spectrometer. 13C NMR spectra were obtained on a 
Bruker Avance-600 spectrometer.  
 
3.4.2 PCR screening of eDNA libraries for KSa genes and clone recovery 
Cosmid DNA isolated from the library served as the template to amplify KSα sequences using 
previously described conditions and degenerate primers (dp:540F-
GGITGCACSTCIGGIMTSGAC and dp:1100R-CCGATSGCICCSAGIGAGTG) (Wawrik et. al. 
2005). Twenty-five microliter PCR reactions contained 50 ng of cosmid DNA, 2.5 µM of each 
primer, 2 mM dNTPs, 1Å~ ThermoPol reaction buffer (New England Biolabs), 0.5 unit Taq 
DNA polymerase (New England Biolabs), and 5%DMSO. PCR was conducted using the 
following touchdown protocol: denaturation (95 °C, 2 min), 8 touchdown cycles [95 °C, 45 s; 65 
°C (−1 °C per cycle), 1 min; 72 °C, 2 min], 35 standard cycles (95 °C, 45 s; 58 °C, 1 min; 72 °C, 
2 min), and a final extension step (72 °C, 2 min). The PCR amplicons were gel-purified (Qiagen) 
and sequenced (Genewiz). A ClustalW-based phylogenetic analysis was carried out on the 
eDNA-derived KSα amplicons using MacVector.  
 
Sublibrary pools from which unique KSα genes were amplified were used as the starting point for 
the recovery of unique KSα containing eDNA clones. Overnight cultures of sublibraries 
containing KSα genes of interest were plated into 96-well microtiter plates at a dilution of 10−6. 
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After 18 h at 37 °C, the diluted cultures were screened by whole-cell PCR using KSα specific 
primers. PCR positive wells were then plated directly on solid media to yield distinct colonies 
that were screened in a second round of whole-cell PCR.  The PCR protocol used was as follows: 
denaturation (95 °C, 5 min), 36 standard cycles (95 °C, 30 s; 55 °C, 30 s; 72 °C, 40s), and a final 
extension step (72 °C, 7 min).  
 
3.4.3 Cosmid retrofitting and integration into Sreptomyces albus 
Recovered cosmids were digested with the rare PsiI to ensure that only the pWEB-TNC vector 
was cut and not the eDNA insert. Each linearized cosmid was then ligated with the 6.81 kb DraI 
fragment from pOJ436. This fragment contains an origin of transfer (oriT), an apramycin 
resistance marker, and elements of the phiC31 attp-attB integration system needed for integration 
into diverse Streptomyces sp. Retrofitted cosmids were transformed into E. coli S17.1 and 
conjugated into Streptomyces using published protocols.  
 
3.4.4 eDNA clone sequencing 
PKS containing cosmids recovered from the eDNA libraries were initially sequenced by 454 
pyrosequencing (Roche) by Memorial Sloan Kettering Cancer Center Genomics Core 
Laboratory. Reads were processed with Newbler (Roche) and Velvet (Zerbino and Birney 2008). 
Sequence gaps between assembled contigs generated during 454 sequencing were completed by 
primer walking (GENEWIZ). The size and deduced role of the open reading frames of 
sequenced cosmids were sequenced by 454-pyrosequencing. ORFs (open reading frames) were 
predicted using MetaGeneMark (Zhu et al. 2010), and predicted ORFs were annotated by Blast 
search and Pfam domain analysis. MacVector was used for sequence manipulation. 
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3.4.5 Transformation-associated recombination (TAR) reassembly of overlapping clones 
One overlapping clone for cosTX451 was subsequently identified in the Tx library using clone-
specific primers designed to recognize the sequence at one end of cosTX451 (TX451R_FW: 
ATCACCTTGTCGGCGTCGTG, TX451R_RV: AGAACCACCTGGAGGTGGTG). Hits were 
identified in subpool TX2512. Overlapping eDNA cosmid (designated cosTX2512) was 
recovered from these pools using the serial dilution method outlined above. The PCR protocol 
used was as follows: denaturation (95, 5 min), 36 standard cycles (95 °C, 30 s; 55 °C, 30 s; 72 
°C, 40s), and a final extension step (72 °C, 7 min).  
The two overlapping eDNA cosmid clones that are predicted to contain the TX451 gene cluster 
(cosTX451 and cosTX2512) were assembled into a single bacterial artificial chromosome (BAC) 
clone using transformation-associated recombination (TAR) in yeast and the pTARa BAC 
shuttle vector. The pathway-specific TAR capture vector was constructed using InFusion cloning 
methodology (Clontech). ~500 bp upstream and downstream homology arms were amplified 
from the cos451 and cosTX2512 cosmids, respectively. For cosTX451 and cosTX2512, 
homology arms needed for TAR recombination were generated using the following primers: 
TX451UPS_FW (5′- CTATCGATCTCGAGGGCTGCGCGACGCGGCCGACC-3′),  
TX451UPS_RV (5′- GTGCTGCATGTTAACACGATGGCGATGGGGCCTCC-3′),  
TX2512DWS_FW (5′-GTTAACATGCAGCACGGCGACGTGGT- 3′),  
TX2512DWS_RV (5′- CCCTGCAGGAGCTCGGGCGCGGCGGAGGTCGACGT-3′)  
Primers TX451UPS_FW and TX2512DWS_RV include 15 bp sequences (underlined) that 
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overlap with BmtI/SphI linearized pTARa capture vector. Primer TX451UPS_RV was designed 
to contain a 15 bp overlap (underlined) with the TX2512DWS_FW primer and an HpaI site 
(bold), which was added to facilitate the subsequent linearization of the pathway-specific pTARa 
capture vector. Gel-purified amplicons (Qiagen) and BmtI/SphI linearized pTARa were 
combined in a standard InFusion cloning reaction (Clontech) to make the pathway-specific 
capture vector. 
 
For TAR assembly, 200 ng of DraI-digested cosTX451 and cosTX2512 were mixed with 100 ng 
of the HpaI-cut pathway-specific capture vector and then transformed into 200 µL of 
Saccharomyces cerevisiae CRY1-2 spheroplasts prepared according to published protocols. 
Transformed spheroplasts were mixed with synthetic complete (SC) top agar (1 M sorbitol, 1.92 
g/L synthetic complete uracil dropout supplement, 6.7 g/L yeast nitrogen base, 2% glucose, and 
2.5% agar) and overlaid onto SC uracil dropout plates. Plates were incubated at 30 °C for 72 h. 
DNA was prepared from 12 yeast colonies using a zymolyase lysis protocol (ZYMO 
RESEARCH) and screened by PCR with primers designed to recognize sequences from 
cosTX451 and cosTX2512. A BAC clone that was “PCR positive” with all the primer sets was 
electroporated into E. coli EPI300 (Epicentre). DNA isolated from the resulting E. coli was was 
fully sequenced by 454 pyrosequencing and confirmed BAC:TX451/2512 to be faithful 
reassemblies of the overlapping cosmid clones.  
 
3.4.6 Heterologous expression and analysis 
cosTX451 and BAC:TX451/2512 transformed into E. coli S17.1 and conjugated into S. albus. 
Spore stocks of S. albus transformed with the retrofitted cosTX451 or BAC:TX451/2512 clone 
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was inoculated in 125 mL baffled flasks containing 50 mL of R5A media (Zhu et al. 2010) (for 1 
L: 100 g sucrose, 0.25 g K2SO4, 10.12 g MgCl2•6H2O, 10 g glucose, 0.1 g casamino acids, 5 g 
yeast extract, 21 g MOPS, 2 g NaOH, 2 mL R2YE trace elements) and grown at 30 °C (200 rpm) 
for 7-10 d. Cultures were then extracted twice with an equal volume of ethyl acetate. The dried 
extracts were dissolved in methanol (2-4 mL/L of culture). The sample was then dried, 
redissolved in 1-2 mL of methanol. The resulting ethyl acetate extract was compared by LC-MS 
to the extract from a similarly grown culture of S. albus transformed with a pTARa empty vector 
control (HPLC conditions: 30 min gradient from 5% to 100% aqueous acetonitrile containing 
0.1% formic acid, C18, 4.6 mm × 150 mm, 1 mL/min). 
 
3.4.7 Compound extraction and purification of Seitomycin, Rabelomycin, 8-Methylrabelomycin, 
1-Deoxo-1-hydroxy-8-O-methylrabelomycin 
Compounds 1, 3 and 4 were isolated from 2 L cultures of S. albus harboring BAC:TX451/2512 
grown (200 rpm at 30 °C) in 125 mL baffled flasks containing 50 mL of R5A media. 7-10 day 
old cultures were extracted with ethyl acetate (1/3, v/v to the culture broth), and the ethyl acetate 
was dried in vacuo. Compounds were isolated from the resulting ethyl acetate extract using two 
rounds of reversed-phase HPLC (C column, 10 18mm × 250 mm, 3.5 mL/min). The first round 
of HPLC (isocratic, 45% acetonitrile containing 0.1% trifluoroacetic acid) yielded three crude 
compounds 1 (13.2 min), 3 and 4 (15.7 min), which were repurified by a second round of HPLC 
using 65%, 75%, and 77% aqueous methanol with 0.1% trifluoroacetic acid to yield compounds 
1 (5 mg L−1), 3 (1.5 mg L−1), and 4 (0.5 mg L−1), respectively. Compound 2 was isolated   from 2 
L cultures of S. albus harboring cosTX451 grown under the same conditions. . 7-10 day old 
cultures were acidifie with 2N HCL (pH 3) and extracted with ethyl acetate (1/3, v/v to the 
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culture broth) and the organic layer was dried in vacuo. Compound 2 was isolated from ethyl 
acetate extract using two rounds of reversed-phase HPLC (C column, 10 18mm × 250 mm, 3.5 
mL/min). The first round of HPLC (isocratic, 50% acetonitrile containing 0.1% trifluoroacetic 
acid) was done to get crude compound 2 (12.9 min) which was repurified by a second round of 
HPLC using 70 % aqueous methanol with 0.1% trifluoroacetic acid to yield compounds 2 (1.0 
mg L−1). Fractions containing desired compounds were dried in vacuo overnight and analyzed by 
MS and NMR.  
Seitomycin (1): 1H NMR (DMSO-d6, 600 MHz): δ 12.3 (s, 1H), 8.0 (d, J = 7.9 Hz, 1H), 7.64 
(d, J = 8.0 Hz, 1H), 7.60 (d, J = 9.4 Hz, 1H), 7.41 (d, J = 9.4 Hz, 1H), 5.80 (t, J = 6.4 Hz, 1H), 
4.72 (br s, 1H), 3.91 (s, 3H), 3.04 (d, J = 17.3 Hz, 1H), 2.83 (d, J = 16.9 Hz, 1H), 2.05 (ddd, J = 
13.9, 6.7, 1.5 Hz, 1H), 1.82 (dd, J = 13.9, 6.1 Hz, 1H), 1.32 (s, 3H),  
 
Seitomycin (1): 13C NMR (DMSO-d6, 150 MHz): δ 192.5, 181.7, 155.9, 154.0, 144.2, 142.6, 
136.4, 135.5, 131.6, 126.8, 126.4, 124.5, 119.1, 118.1, 68.2, 64.7, 57.6, 45.9, 45.5, 30.9. 
 
Rabelomycin (2): 1H NMR (DMSO-d6, 600 MHz): δ 12.28 (s, 1H), 11.64 (s, 1H), 7.8 (t, J = 
8.0 Hz, 1H), 7.49 (d, J = 8.0 Hz, 1H), 7.35 (d, J = 8.0 Hz, 1H), 7.15 (s, 1H), 3.47 (br s, 1H), 3.07 
(s, 2H), 2.95 (d, J = 15.0 Hz, 1H), 2.68 (d, J = 15.0 Hz, 1H), 1.32 (s, 3H)  
 
Rabelomycin (2): 13C (DMSO-d6, 150 MHz): δ 195.8, 191.0, 183.4, 162.3, 160.6, 152.0, 137.6, 
137.5, 135.8, 128.7, 123.6, 121.5, 118.6, 116.7, 115.5, 71.2, 53.2, 43.6, 29.5  
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8-O-Methylrabelomycin (3): 1H NMR (DMSO-d6, 600 MHz): δ 12.9 (s, 1H), 7.81 (t, J = 8.0 
Hz, 1H), 7.53 (dd, J = 1.5, 8.0 Hz, 1H), 7.46 (dd, J = 1.5, 8.0 Hz, 1H), 6.8 (s, 1H), 4.9 (br s, 1H), 
3.96 (s, 3H), 3.03 (s, 1H), 2.91 (d, J = 15.0 Hz, 1H), 2.83 (s, 1H), 2.61 (s, 1H), 1.3 (s, 3H) 
 
8-O-Methylrabelomycin (3): 13C (DMSO-d6, 150 MHz): δ 195.7, 187.3, 186.2, 162.1, 160.0, 
150.3, 140.0, 138.3, 136.3, 123.8, 121.8, 121.6, 119.6, 118.9, 118.7, 71.7, 57.3, 54.1, 44.5, 30.2 
 
1-Deoxo-1-hydroxy-8-O-Methylrabelomycin (4): 1H NMR (DMSO-d6, 600 MHz): δ 13.0 (s, 
1H), 7.91 (d, J = 8.4 Hz, 1H), 7.76 (d, J = 8.4 Hz, 1H), 7.61 (d, J = 8.4 Hz, 1H), 7.10 (s, 1H), 
5.61 (m, 1H), 4.8 (br s, 1H), 4.5 (br s, 1H), 4.09 (s, 3H), 2.93 (d, J = 17.0 Hz, 1H), 2.7 (br m, 
2H), 2.13 (dd, J = 14.1, 5.5 Hz, 1H), 1.3 (s, 3H)  
 
1-Deoxo-1-hydroxy-8-O-Methylrabelomycin (4): 13C (DMSO-d6, 150 MHz): δ 
189.0, 187.0, 161.0, 160.7, 148.4, 137.8, 137.2, 135.0, 132.2, 124.4, 120.2, 120.1, 119.4, 117.2,  





















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Phylogeny-Guided Discovery and Heterologous Expression Studies of Novel 
Type II PKS Gene Clusters  
 
4.1 Introduction 
Soil microbiome is a vast reservoir of genomic diversity and metabolic pathways that are 
intimately associated with novel natural products. Natural product discovery programs have 
traditionally relied on random screening of microbial species to identify new chemistry in nature 
(Cragg and Newman 2013). However, microorganisms are difficult to culture using laboratory-
based methods. It is now common knowledge that direct visualization of microorganisms in a 
natural sample by staining and microscopic studies hints toward a population count one to two 
orders of magnitude higher than that measured by culturing from that same sample. This has led 
to an anomaly: while some microorganisms have been extremely well studied, a great majority 
has not been explored at all. The data from 16S ribosomal 
RNA (or 16S-rRNA) gene-sequence studies provide 
probably the strongest support to the notion that our census 
of microbial populations is far from comprehensive. 
Therefore, harnessing the biosynthetic capacity of 
environmental microbial species to discover bioactive 
chemical compounds is contingent upon overcoming the 
“culture bias”.	 
Recent advancements in various next-generation 









pWEB-based cosmids carrying 
30 ~ 40 kb eDNA fragments 
Figure 48. Metagenomic approach to natural 
product discovery. Microbial DNA is isolated 
from the environment and cloned into E.coli 
based vector that can be cultured under 
laboratory conditions.  
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explosion in the number of studies exploring species diversity of microbial environments (Figure 
48). 16S rRNA sequence studies have confirmed that soil is an environment particularly rich in 
microbial diversity and hence a promising source of novel chemistry (Hugenholtz, Goebel et al. 
1998). Even soil from environments expected to have low diversity, such as landfills or other 
contaminated sites, have turned out to be above-average (Nüsslein and Tiedje 1998; Lloyd-Jones 
and Lau 1998). Therefore, a systematic sequence-based screening of the soil metagenome should 
enable the functional characterization of diverse biosynthetic pathways that lay hidden in nature 
(Kallifidas and Brady 2012).  
In this chapter, I report the use of a highly conserved biosynthetic gene as a phylogenetic marker 
to identify novel gene clusters. This approach can serve to offset new natural product discovery. 
I use short conserved biosynthetic gene sequences (sequence tags) amplified from soil microbial 
DNA as phylogenetic units to target the discovery of novel aromatic polyphenols (type II 
polyketides) from the environment. Aromatic polyketides are a structurally diverse collection of 
metabolites having important antimicrobial and anticancer properties (Hertweck, Luzhetskyy et 
al. 2007). Even though gene clusters encoding biosynthesis of these metabolites can differ 
substantially in gene content, they all contain a conserved set of three proteins: ketosynthase 
alpha (KSα) ketosynthase beta/chain length factor (KSβ) and acyl carrier protein (ACP) forming a 
polyketide synthase (PKS) unit known as the minimal PKS. Shotgun-sequencing data as well as 
PCR-based studies indicate that environmental DNA (eDNA) samples are rich in unique minimal 
PKS genes (Kang and Brady, 2014; Feng, Kallifidas et al. 2011; Pang, Tan et al. 2008; Seow et 
al. 1997). Significant structural diversity, both in terms of carbon skeleton and functional groups, 
coupled with a wide variety of biological activities of this biosynthetic subgroup make aromatic 
polyphenols viable targets for the phylogeny-based natural product discovery approach. 
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Our efforts to identify novel polyketide natural products began by cataloguing eDNA-derived 
type II PKS gene clusters whose ketosynthase beta (KSβ) sequence-tag was phylogenetically 
distinct from any known KSβ sequence. In this study, I used polymerase chain reaction (PCR) 
amplicon sequences (sequence tags) of KSβ genes from archived soil eDNA libraries to explore 
the structural and biosynthetic diversities of aromatic polyphenols. The KSβ gene forms a subunit 
of the minimal PKS that is responsible for generating the non-reduced intermediate in aromatic 
polyketide biosynthesis (Figure 49). KSβ genes have proven to be robust phylogenetic markers 
that represent structural variations in the carbon skeleton of the natural products derived
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Figure 49. Overview of the phylogeny-guided strategy for the discovery of new natural products. eDNA from soil is 
used to construct cosmid megalibraries (> 10 000 000 clones), which are arrayed as pools of unique 5000-membered 
sublibraries. Aromatic polyketide min-PKS KSβ genes are amplified in PCR reactions with degenerate primers using 
DNA from each unique sublibrary within the megalibraries as template. The phylogenetic grouping of eDNA 
sequences with KSβ sequences from gene clusters that encode novel natural products is used to guide the recovery of 
clones containing gene clusters of interest from specific sublibraries. Heterologous expression of bioinformatically 
unique eDNA-derived complete gene clusters can be used to expand the structural diversity of natural products.  
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from type II PKS biosynthetic systems (Winter, Sloman et al. 2013; Feng et al. 2011; Sullivan 
2005; Nakagawa, Omura et al. 1987). In other words, this single gene can predict the general 
class of a type II PKS gene cluster.  
 
The eDNA-derived KSβ amplicons were mapped onto a phylogenetic tree constructed using KSβ 
genes from functionally characterized type II PKS clusters. A	number of amplicons were found 
to fall into the well-defined type II PKS clades, such as anthracycline, tetracycline, angucycline, 
pentangular polyphenol etc. (Kang and Brady 2014; Hertweck 2009). Close inspection of the 
KSβ gene phylogeny indicated that our 
soil eDNA libraries contain biosynthetic 
gene clusters that did not align with any 
known or functionally characterized type 
II PKS pathways (Figure 50). These 
clusters, therefore, could potentially 
encode for natural products with novel 
chemical scaffold and lead to new therapeutics. A selective few of these potentially novel type II 
PKS biosynthetic clusters were recovered from the archived libraries and carried forward for 
heterologous expression studies.  
 
4.2 Results 
4.2.1 KSβ sequence-guided screening of soil eDNA libraries.  
To identify novel gene clusters encoding type II PKS, soil eDNA libraries were screened with 
degenerate primers targeting the KSβ gene of the min-PKS. KSβ genes clade into groups that 
Novel gene cluster: Novel compound? 
 Known compound 
 Minor modification 
 Known compound 
Minor modification  
Outgroup 
Figure 50. Biosynthetic marker phylogeny. Phylogenetic analysis to 
identify biosynthetic gene clusters that do not clade with functionally 
characterized pathways could lead to natural products with novel 
scaffold. 
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correlate strongly with the specific aromatic polyketide structural classes that are encoded by the 
gene clusters (Kang and Brady 2013; Feng et al. 2011; Ridley, Lee et al. 2008). Based on this 
observation, I surmised that it could be possible to systematically screen multimillion-member 
eDNA libraries for biosynthetic gene clusters encoding novel members of aromatic polyketide 
structural classes using PCR-amplified min-PKS gene fragments as sequence tags. Phylogenetic 
trees were constructed with the resulting eDNA KSβ amplicon sequences and sequences from 
functionally characterized type II PKS gene clusters available from GenBank database. Through 
this analysis, from 78 sequenced type II PKS clones, I identified a group of KSβ sequence tags 
from our Anza Borrego Desert (AB) and Arizona (AZ) eDNA libraries that were 
phylogenetically distant from KSβ genes from any functionally characterized type II PKS gene 
clusters (Figures 51, 52). Gene clusters carrying these “unique” KSβ genes could potentially 
encode for novel type II PKS derived metabolites. All these clones were, therefore, recovered 
from the archived libraries and fully sequenced. Based on phylogenetic comparison of the KSβ 
genes and the gene content of each cluster, I identified three type II PKS pathways that were of 
particular interest: AB1215, AB1449 and AZ1237 (Figure 52).  
4.2.2 Overlapping clone recovery 
Sequencing data for all three cosmid clones, AB1215, AB1449 and AZ1237 indicated that the 
above-mentioned biosynthetic clusters were not completely captured in one cosmid clone. This 
sequence data was subsequently used to guide the recovery of additional overlapping cosmids in 
order to reconstruct the original pathways. Sequencing and bioinformatics annotation of each set 
of overlapping cosmid clones revealed biosynthetic gene clusters flanked by collections of genes 
predicted to encode primary metabolic enzymes, suggesting that all three gene clusters were 
recovered in their entirety on the overlapping cosmids.  
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Figure 52. A part of the maximum likelihood tree of partial KSβ gene sequences is shown. AZ and AB denote 
amplicon sequences derived from Arizona and California desert soil eDNA libraries, respectively. The specific 
group of eDNA sequence tags used in this study are highlighted in red boxes.  
 
4.2.3 Gene cluster analysis of complete AB1215, AB1449 and AZ1237 pathways 
Biosynthetic highlights of AB1215/183 pathway. 
Antibiotics containing sugar moieties are promising, especially regarding their bioactivity and 
the engineering of new/ novel analogues through glycodiversification (Kharel et al. 2012). 
Sequence analyses of this biosynthetic gene cluster revealed 8 ORFs that could potentially be 
involved in the deoxysugar biosynthetic pathways (ORFs 16, 17, 18, 19, 20, 22, 23 and 26) 
(Figure 53). The cluster also contains genes for sugar aminotransferase. The cluster, therefore, 
encodes for the biosynthesis of type II PKS derived small molecule with aminodeoxy sugars. In 
	 94 
addition, there is a gene for potential C-glycosylation, which is not very common (Rohr and 
Thiericke, 1992; Murenets 1990) and may lead to a structurally novel compound (Figure 53). 





















Figure 53. ORF diagram and gene table for Type II PKS pathway AB1215/183. ORFs were predicted using 
MetaGeneMark and predicted ORFs were annotated by Blast search and Pfam domain analysis. MacVector was 




1# 3# 5# 7# 9# 11# 15#13# 17# 19# 21# 23# 25# 27# 29# 31# 33#
Gene Clone Size Deduced function of protein I/S% Origin Accession no.
orf1 1215 648 transcriptional regulator, TetR family 65/77 Salinispora pacifica] WP_026321730.1
orf2 1215 960 AfsA-like protein 37/49 Streptomyces sp. WP_012999106.1
orf3 1215 726 two component transcriptional regulator 48/62 Streptomyces sp. CAI78073.1
orf4 1215 1461 putative oxygenase 68/78 Streptomyces sp. AAK06782.1
orf5 1215 327 polyketide cyclase 69/77 Streptomyces sp. AAO65361.1
orf6 1215 1269 polyketide beta-ketoacyl synthase 79/90 Streptomyces sp. WP_018554453.1
orf7 1215 1236 polyketide chain length factor 73/84 Streptomyces sp. WP_018383118.1
orf8 1215 273 acyl carrier protein 65/75 Streptomyces sp. WP_031488005.1
orf9 1215 783 ketoacyl reductase 79/88 Streptomyces sp. WP_015037164.1
orf10 1215 948 aromatase 66/80 Streptomyces sp. CAH10113.1
orf11 1215 1488 oxidoreductase 54/62 Streptomyces sp. WP_030791015.1
orf12 1215 351 reductase 65/79 Streptomyces sp. AID47011.1
orf13 1215 411 short-chain dehydrogenase 77/91 Streptomyces sp. WP_044378901.1
orf14 1215 1215 MFS transporter 59/74 Streptomyces sp. WP_015610259.1
orf15 1215 1599 methylmalonyl-CoA carboxyltransferase 81/90 Streptomyces sp. WP_018511400.1
orf16 1215 1068 NDP-hexose synthetase 65/78 Streptomyces sp. AID46996.1
orf17 1215 1026 dTDP-glucose 4,6-dehydratase 74/85 Streptomyces sp. WP_020939985.1
orf18 1215 1338 NDP-hexose 3,4-dehydratase 79/89 Streptomyces sp. AAF72550.1
orf19 1215 1398 NDP-D-glucose 2,3-dehydratase 62/72 Streptomyces sp. WP_031943735.1
orf20 1215 999 putative dNDP-hexose 3-ketoreductase 55/66 Streptomyces sp. CAF31369.2
orf21 1215 1134 sugar 4-aminotransferase 61/74 Streptomyces sp. AGI99479.1
orf22 1215 594 dTDP-4-dehydrorhamnose 3,5-epimerase 59/71 Streptomyces sp. WP_030554130.1
orf23 1215 864 NDP sugar epimerase 63/77 Streptomyces sp. WP_026241366.1
orf24 1215 645 antibiotic biosynthesis monooxygenase 51/60 Streptomyces sp. WP_030564775.1
orf25 1215 831 methyltransferase 41/59 Streptomyces sp. WP_030410217.1
orf26 1215 1140 putative C-glycosyltransferase 44/58 Streptomyces sp. CAF31363.2
orf27 1215 585 reductase 66/76 Streptomyces sp. AID47004.1
orf28 1215 513 MerR family transcriptional regulator 68/80 Streptomyces sp. WP_027731212.1
orf29 1215 1212 MFS transporter 58/72 Streptomyces sp. WP_037683816.1
orf30 1215 1764 biotin carboxylase of acetyl-CoA carboxylase73/82 Streptomyces sp. WP_023547158.1
orf31 183 657 putatie oxidoreductase 44/56 Streptomyces sp. AHW57793.1
orf32 183 948 hypothetical protein 43/55 Streptomyces sp. AHW57774.1
orf33 183 1284 putative transposase 84/93 Streptomyces sp. WP_031498885.1









and the presence of a combination of post-PKS tailoring enzyme encoding genes such as C-
glycosyltransferase the sugar aminotransferase found on clone AB1215/183, I selected to study 
this gene cluster using heterologous expression methods.  
 





Figure 54. ORF diagram and gene table for Type II PKS pathway AB1449/647. ORFs were predicted using 
MetaGeneMark and predicted ORFs were annotated by Blast search and Pfam domain analysis. MacVector was 
used for sequence manipulation. 
1" 3" 5" 7" 9" 11" 15"13" 17" 19" 21" 23" 25" 27" 29"
Gene Clone Size Deduced function of protein I/S% Origin Accession no.
orf1 1449 3003 SARP family transcriptional regulator                      40/51                        Streptomyces sp.     WP_030714058.1
orf2 1449 636 NADH-flavin reductase             54/66           Streptomyces sp.     WP_012891744.1
orf3 1449 867 hypothetical protein                 38/47                      Streptomyces sp.    AIA07021.1
orf4 1449 1182 cytochrome P450 70/81 Streptomyces sp.    WP_019890099.1
orf5 1449 1496 pyridine nucleotide-disulfide oxidoreductase 61/70                     Streptomyces sp.     WP_045557816.1
orf6 1449 357 dehydrogenase 34/46 Streptomyces sp.        WP_028419658.1
orf7 1449 645 C-5 anthrone oxidase 66/84                                    Streptomyces sp.   AAC98518.1
orf8 1449 1209 cytochrome P450 27/45                             Streptomyces sp    WP_037831154.1
orf9 1449 1380 NDP-hexose 2,3-dehydratase 59/69                  Streptomyces sp. WP_037825067.1
orf10 1449 972 NDP-4-keto-6-deoxyhexose 4-ketoreductase 53/65                       Streptomyces sp.   AAL14256.1
orf11 1449 720 methyltransferase 53/67 Streptomyces sp.   CAA05643.1
orf12 1449 1110 NDP-hexose aminotransferase          77/86                                              Streptomyces sp.      ABV49595.1
orf13 1449 612 dTDP-4-dehydrorhamnose 3,5-epimerase 71/83                                               Streptomyces sp.      WP_003963466.1
orf14 1449 1182 glycosyltransferase 61/72 Streptomyces sp.      ABO28818.1
orf15 1449 1494 FAD-dependent oxidoreductase 66/74        Streptomyces sp.      CCA59273.1
orf16 1449 348 putative oxygenase 54/56 Streptomyces sp. CAA60567.1
orf17 1449 327 putative cyclase 79/83                                   Streptomyces sp. CAH10118.1
orf18 1449 1269 putative ketosynthase 80/88                                 Streptomyces sp. AAK06784.1
orf19 1449 1269 putative chain length factor 69/82            Streptomyces sp. CBH32808.1
orf20 1449 249 acyl carrier protein 64/76                                     Streptomyces sp. AGO50612.1
orf21 1449 1719 acetyl-CoA carboxyltransferase 69/77 Streptomyces sp. WP_030283707.1
orf22 1449 558 biotin carboxylase carrier protein 67/80 Streptomyces sp. AAG30192.1
orf23 1449 1389 pyruvate carboxylase subunit A 63/75 Streptomyces sp. WP_046930293.1
orf24 1449 795 ketoacyl reductase 76/86 Streptomyces sp. WP_031121806.1
orf25 647 852 putative aromatase 63/74 Streptomyces sp. BAJ07855.1
orf26 647 1149 FAD-binding monooxygenase 62/72 Streptomyces sp. WP_033205650.1
orf27 647 1026 aldo/keto reductase 69/80 Streptomyces sp. WP_046709454.1
orf28 647 666 TetR family transcriptional regulator 61/72 Streptomyces sp. WP_033175331.1
orf29 647 630 FMN reductase 67/78 Streptomyces sp. WP_012895574.1









Analysis of this biosynthetic gene cluster indicated that there are 4 ORFs that could potentially 
be involved in the biosynthesis of deoxysugar (ORFs 9, 10, 13 and 14) (Figure 54). In addition, 
there is putative hexose aminotransferase potentially leading to aminodeoxy sugar biosynthesis. 
There is a putative C-5 anthrone oxidase (ORF 7) gene in this cluster. This gene is often 
responsible for Baeyer-Villiger type oxidative cleavage of a ring system followed by 
rearrangements of the carbon scaffold of aromatic polyketides generating novel carbon motif. 
Similar genes are also found in certain angucycline gene clusters (GilOI, JadH and UrdM) (Li 
and Piel 2002). This cluster encodes for enzymes that can carry out additional post-PKS tailoring 
reactions, including the O-methylation, which is promising with regards to structural 
diversification (Figure 54). Based on the above analysis, I chose to carry forward this 
AB1449/647 type II PKS pathway for heterologous expression studies.  
 
Biosynthetic highlights of AZ2250/1237/2224 pathway. 
As mentioned earlier, glycosylation is one of the most important tailoring steps in aromatic 
polyketide biosynthesis. In this particular pathway, there are 5 ORFs (ORFs 14, 17, 19, 22 and 
36) that could potentially lead to glycosylated natural product (Figure 55). Three of these genes 
are actually putative glycosyltransferases. Therefore, this pathway could produce an aromatic 
polyphenol with oligosaccharide attachment. Additionally, the presence of a sugar O-
methyltransferase can impart further structural diversification (Figure 55). The above features 
made this AZ2250/1237/2224 cluster of substantial interest to us, and it was taken forward for 








Figure 55. ORF diagram and gene table for Type II PKS pathway AZ2250/1237/2224. ORFs were predicted using 
MetaGeneMark and predicted ORFs were annotated by Blast search and Pfam domain analysis. MacVector was 
used for sequence manipulation. 
 
4.2.4 TAR cloning for reconstruction type II PKS pathways AB1215, AB1449 and AZ1237 
It has been shown that transformation associated recombination (TAR) in Saccharomyces 
1" 3" 5" 7" 9" 11" 15"13" 17" 19" 21" 23" 25" 27" 29" 31" 33" 35" 37"
Gene Clone Size Deduced function of protein I/S% Origin Accession no.
orf1 2250 1698 ABC transporter ATP-binding protein 46/59 Streptomyces sp.     WP_030261462.1
orf2 2250 1695 ABC transporter ATP-binding protein 43/59           Kutzneria albida WP_025354879.1
orf3 2250 1902 SARP family transcription regulator 49/62                     Kutzneria albida AHH93931.1
orf4 2250 1014 ArsR family transcriptional regulator 53/67 Amycolatopsis decaplanina WP_007030015.1
orf5 2250 945 hypothetical protein 85/89                   Amycolatopsis rifamycinica WP_043782961.1
orf6 2250 903 short-chain dehydrogenase 94/96 Streptomyces sp.        WP_037683050.1
orf7 2250 666 TetR family transcriptional regulator 94/97                                 Streptomyces sp.   WP_044575537.1
orf8 2250 1254 hypothetical protein 43/60                           Streptomyces sp    WP_030677244.1
orf9 2250 984 alcohol dehydrogenase  34/51                 Ktedonobacter racemifer EFH82381.1
orf10 2250 1149 oxidoreductase 54/64                       Streptomyces sp.   WP_014182277.1
orf11 2250 825 sugar O-methyltransferase 59/72                                            Streptomyces sp.      AAG42854.1
orf12 2250 633 polyketide synthase 41/57                                             Streptomyces sp.      WP_019662161.1
orf13 1237 651 TetR family transcriptional regulator 55/70 Streptomyces sp.      WP_033175331.1
orf14 1237 1209 glycosyltransferase 56/67 Streptomyces sp.      AAF00217.1
orf15 1237 612 FMN reductase 67/79 Streptomyces sp. WP_012895574.1
orf16 1237 636 TetR family transcriptional regulator 54/68                                 Streptomyces sp. WP_033175331.1
orf17 1237 840 NAD-dependent epimerase 55/67                           Streptomyces sp. WP_009714477.1
orf18 1237 1146 sugar O-methyltransferase 42/58          Streptomyces sp. ACQ63636.1
orf19 1237 1179 glycosyltransferase 44/56                                     Streptomyces sp. ABO28818.1
orf20 1237 327 putative polyketide cyclase 81/89 Streptomyces sp. AAO65345.1
orf21 1237 1476 monooxygenase 71/78 Streptomyces sp. WP_031488013.1
orf22 1237 1164 glycosyltransferase 63/71 Streptomyces sp. ABO28818.1
orf23 1237 708 anthrone monooxygenase 66/78 Streptomyces sp. WP_041993338.1
orf24 1237 1194 cytochrome P450 26/42 Streptomyces sp. WP_030882035.1
orf25 1237 906 putative dTDP-1-glucose synthase 71/80 Streptomyces sp. AAF73461.1
orf26 1237 1761 acetyl-CoA carboxylase 74/83 Streptomyces sp. WP_028959689.1
orf27 1237 1584 methylmalonyl-CoA carboxyltransferase 81/90 Streptomyces sp. WP_030624360.1
orf28 1237 1491 bifunctional oxygenase-reductase protein 66/72 Streptomyces sp. AAT64432.1
orf29 1237 945 cyclase 68/78 Streptomyces sp. WP_030683252.1
orf30 1237 786 polyketide ketoreductase 74/85 Streptomyces sp. WP_015037164.1
orf31 1237 297 acyl carrier protein 62/77 Streptomyces sp. WP_031943729.1
orf32 1237 1218 chain length factor 78/86 Streptomyces sp. WP_018383118.1
orf33 1237 1233 ketoacyl synthase 81/88 Streptomyces sp. WP_017237282.1
orf34 1237 711 hypothetical protein 49/57 Streptomyces sp. AHW57770.1
orf35 1237 771 SARP-family transcriptional regulator 40/56 Streptomyces sp. WP_020939953.1
orf36 1237 1311 UDP-glucose 4-epimerase 44/59 Streptomyces sp. WP_037813783.1








cerevisiae could be used to reconstruct large continuous stretches of DNA captured on 
overlapping cosmid clones (Kim et al. 2010). To reassemble AB1215 and AB183, AB1449 and 
AB647, and AZ2225, AZ1237 and AZ2250 into single DNA fragments that could be used in 
heterologous expression studies, cosmids and their corresponding specific yeast capture vector 
were co-transformed into S. cerevisiae and allowed to recombine (Figure 56). The bacterial 
artificial chromosomes (BACs) constructed in this experiment were completely sequenced and 
found to be faithful reassemblies of the overlapping eDNA sequences. These newly assembled 
large insert clones were conjugated into S. albus and examined for the production of clone 
specific metabolites.  







Recombination (TAR) in Yeast
Transformation Associated Recombination 
Figure 56. Transformation Associated Reassembly (TA ) f overlapping eDNA clones in yeast. 
Overlapping cosmid clones for the sequence of interest were screened for and recovered from eDNA 
library and assembled into one bacterial artificial chromosome (BAC) clone. 
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4.2.5 Heterologous expression of the eDNA-derived gene clusters 
In order to examine the AB1215, AB1449 and AZ1237 pathways for production of metabolites 
encoded within the clusters, each set of three overlapping eDNA cosmid clones (AB1215, 
AB183; AB1449, AB647; AZ2250, AZ1237, AZ2224) was assembled into bacterial artificial 
chromosomes (BAC-AB1215/183, BAC-AB1449/647 and BAC-AZ22250/1237/2250) using 
pathway specific pTARa (E. coli:yeast:Streptomyces) shuttle capture vectors and transformation-
associated recombination (TAR) in yeast ( Kim et al. 2010) (Figure 56). These BAC constructs 
were sequenced to ensure correct assembly and subsequently conjugated into Streptomyces albus 
by intergenic conjugation and integrated into the Streptomyces genome using the ΦC31 
integrase.  
 
Figure 57. S. albus transformed with eDNA-derived type II PKS pathway BAC-AB1215/183 was screened for the 
production of clone specific metabolites. LC-MS analysis of crude ethyl acetate extract of Streptomyces culture 
broth showed one major clone specific peak with m/z 761. No clone specific peaks were observed on LCMS 









For heterologous expression, the resulting strains, S. albus BAC-AB1215/183, S. albus BAC-
AB1449/647 and S. albus BAC-AZ22250/1237/2250, were grown in R5A liquid media for 10 
days at 30 °C. LC−MS analysis of ethylacetate extracts derived from these cultures showed the 
presence of one major clone-specific peak for BAC-AB1215/183 and BAC-AB1449/647 each 
(Figure 57 and 58, respectively). BAC-AZ22250/1237/2250 showed peaks corresponding to 













Figure 58. S. albus transformed with eDNA-derived type II PKS pathway BAC-AB1449/647 was screened for the 
production of clone specific metabolites. LC-MS analysis of crude ethyl acetate extract of Streptomyces culture 
broth showed one major clone specific peak. No clone specific peaks were observed on LCMS analysis with S. 



















Figure 59. S. albus transformed with eDNA-derived type II PKS pathway BAC-AZ22250/1237/2250 was screened 
for the production of clone specific metabolites. LC-MS analysis of crude ethyl acetate extract of Streptomyces 
culture broth showed one major clone specific peak. A control was carried out using S. albus transformed with 
cosmid AZ1237 which did not show any clone specific peaks on LCMS analysis.  
 
4.2.6 Complementation of deoxysugar biosynthesis  
Extensive sequence analysis of the three type II PKS pathways revealed that AB449/647 and 
AZ2250/1237/2224 are missing key genes that are required to initiate sugar biosynthesis. The 
AZ2250/1237/2224 pathway has multiple glycosyltransferase genes, but it lacks two critical 
genes required for deoxysugar biosynthesis: dNDP-4-keto-6-deoxyglucose 3,5-epimerase and 
dNDP-4-ketohexulose reductase, while the AB449/647 pathway is missing the dNDP-D-glucose 
synthase gene. Therefore, in all likelihood, pathways AB449/647and AZ2250/1237/2224 are 





These sugar biosynthesis genes appear in the primary metabolic background in some, but not all, 
Streptomyces sp. (Rodriguez, Menzella et al. 2009). The early genes required for deoxysugar 
biosynthesis were therefore provided in trans (pIJRham). The rhamnose sugar biosynthetic 
operon (oleL, oleS, oleE, and oleU) (Rodriguez, Oelkers et al. 2000) from oleandromycin 
biosynthesis was cloned under the control of the constitutive ermE* promoter within the 
conjugative integrative shuttle expression vector pIJ10257 (Hong, Hutchings et al. 2005). The 
pIJRham construct was generated by Dr. Haak-Soo Kang. The pIJRham construct was 
subsequently transformed into E. coli S17.1 and conjugated into S.albus/AB1449/647 and 
S.albus/AZ2250/1237/22224 to yield S.albus/AB1449/647/pIJRham and 
S.albus/AZ2250/1237/22224/pIJRham, respectively.  
 
4.3 Discussion 
Soil metagenome is a rich resource for the discovery of novel natural products. In this chapter, I 
demonstrate that it is possible to identify collections of natural product gene clusters that encode 
novel metabolites using the sequence tag-based metagenomic screening approach. I show that 
sequence tags falling in between two well-defined clades associated with different structural 
classes can help identify novel biosynthetic gene clusters. 
 
On the basis of the differences in min-PKS gene phylogeny, I shortlisted a collection of type II 
PKS gene clusters whose the KSβ genes clade differently from any known existing biosynthetic 
clusters of the same family of natural products. The individual proteins that constitute the min-
PKS (KSα, KSβ, and ACP) are highly conserved across all type II PKS gene clusters. KSβ 
phylogenetic tree correlates closely with differences in the core polyketide structure (carbon 
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chain length and cyclization pattern) encoded by the gene cluster from which the min-PKS arises 
(Khosla 2008). KSβ genes have thus proven to be useful phylogenetic markers for predicting 
differences in polyketide core structures encoded by type II PKS gene clusters (Wawrik, Kerkhof 
et al. 2005). 
 
I carried out our phylogeny-based bioinformatics analysis on KSβ genes from 78 type II PKS 
gene clusters from our archived megalibraries constructed using Anza Borrego Desert soil from 
California (AB library) and Arizona (AZ library). Our phylogenetic analysis led to the 
identification of three unique eDNA encoded biosynthetic pathways, AB1215, AB1449 and 
AZ1237, containing Type II PKS gene clusters that do not clade with any known or functionally 
characterized pathways. They could therefore encode for and produce molecules with novel 
chemical scaffolds. These cosmid-based clones were fully sequenced and analysis of this 
sequencing data indicated that these gene clusters were only partially captured. Incomplete 
biosynthetic pathways either remain silent during heterologous expression studies, or they 
produce intermediate compounds or shunt products from the pathway. It was therefore essential 
that I recover each pathway in its entirety. It’s been shown that an eDNA library of 10 to 15 
million clones is likely to contain collections of clones encompassing complete PKS gene 
clusters and permit the recovery of overlapping clones from biosynthetic gene clusters found in 
the genomes of uncultured bacteria (Kim et al. 2010). I then identified, from the same archived 
libraries (consisting of ~107 clones) where these above mentioned pathways were originally 
found, multiple overlapping gene clusters and reconstructed these gene clusters on bacterial 
artificial chromosome (BAC) clones using Transformation Associated Recombination (TAR) in 
yeast (Kim et al. 2010). 
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Type II PKS pathway AB1215 and AB1449 were recovered on two overlapping cosmids, 
AB1215, AB183 and AB1449, AB647, respectively. AZ1237 was fully captured on three 
different cosmids, AZ2250, AZ1237, AZ2224. All the overlapping fragments were sequenced 
and the open reading frames (ORFs) of each pathway were assessed using bioinformatics tools. 
This analysis confirmed that these clusters were quite unique in their gene content. All three 
pathways encode for deoxysugar biosynthesis, which make them promising, both from structural 
and bioactivity perspective. AB1215/183 also contain genes for sugar aminotransferase and C-
glycosylation, making it an interesting pathway to pursue. AB1449/647 again contains 
aminodeoxysugar biosynthesis genes. In addition, there is a putative C-5 anthrone oxidase gene 
in this cluster which can effect oxidative rearrangements and lead to a unique carbon skeleton. 
Pathway AZ2250/1237/2224 encodes for multiple glycosyltransferases, which can potentially 
lead to a unique aromatic polyphenol natural product with oligosaccharide side chain.  
 
Based on both our phylogenetic analysis and ORF predictions, these three pathways were 
reassembled into large insert BAC clones using TAR cloning in yeast and subsequently 
examined for clone specific metabolite production in heterologous expression host, S. albus. 
BAC-AB1215/183 and BAC-AB1449/647 each conferred the production of one clone-specific 
metabolite in Streptomyses, whereas three clone specific metabolites were identified from 
heterologous expression of BAC-AZ22250/1237/2250 pathway. Characterization of these 
metabolites would lead to further information regarding the biosynthetic potential of these gene 
clusters.  
 
Close inspection of the three type II PKS pathways indicated that pathways AB449/647 and 
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AZ2250/1237/2224 are missing key genes that are required to initiate the deoxysugar 
biosynthesis. Therefore, it is likely that pathways AB1449/647 and AZ2250/1237/2224 are 
producing just the aglycone moiety and not the final glycosylated product encoded in the 
pathway. The critical sugar biosynthesis genes were then provided in trans using pIJRham that 
contains the rhamnose sugar biosynthetic operon. Systematic comparative analysis of the 
metabolites produced by S. albus exconjugants harboring the BAC clones with and without the 
pIJRham construct should lead to definitive answers. Work is underway to better understand the 
metabolites produced by these pathways.  
 
The work presented in this chapter demonstrates that one can rapidly access untapped chemical 
diversity of highly complex environmental microbiomes using single gene sequence tags. This 
methodology is scalable using high throughput sequencing technology and large eDNA libraries. 
The current study strengthens the idea that sequence-based eDNA mining approaches like those 











4.4 Materials and Methods 
4.4.1 Bioinformatic analysis of KSβ sequence tags 
PCR amplicons were gel purified (Qiagen) and Sanger-sequenced (Genewiz). Approximately 
600bp of KSβ gene fragments from each amplicon were aligned using ClustalW. Phylogenetic 
analysis and pairwise distant calculations were performed using MEGA5.1 (Tamura, Peterson et 
al. 2011). All PCR was performed using BioRad Tetrad thermocycler. 
 
4.4.2 Clone recovery and bioinformatics analysis 
eDNA clone AB1215, AB1449 and AZ1237 were recovered from the AB (Anza Borrego) and 
AZ eDNA libraries by serial dilution of the 5,000-member sub-pool from which the amplicons 
were originally amplified. For this, an overnight culture of each sub-pool was inoculated into 96-
well microtiter plates at a dilution of 10−6. After 18 h of shaking at 37 °C, the diluted cultures 
were screened by whole-cell PCR using the KSβ screening primers (dp:KS-
TTCGGSGGITTCCAGWSIGCSATG and dp:ACP-TCSAKSAGSGCSAISGASTCGTAICC) 
(Seow et al. 1997) and touchdown PCR protocol. PCR positive wells were plated onto solid 
media (LB agar) to yield distinct colonies that were screened individually in a second round of 
whole-cell PCR that was conducted using the following touchdown protocol: denaturation (95 
°C, 2 min), 8 touchdown cycles [95 °C, 45 s; 65 °C (−1 °C per cycle), 1 min; 72 °C, 1 min], 35 
standard cycles (95 °C, 45 s; 58 °C, 1 min; 72 °C, 1 min) and a final extension step (72 °C, 2 
min). Each 25 µL PCR reaction contained 50 ng of cosmid DNA, 2.5 µM of each primer, 2 mM 
dNTPs, 1X ThermoPol reaction buffer (New England Biolab), 0.5 units Taq DNA polymerase 
and 5% DMSO.  
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4.4.3 Cosmid retrofitting and integration into Streptomyces albus 
Recovered cosmids were digested with the rare PsiI to ensure that only the pWEB-TNC vector 
was cut and not the eDNA insert. Each linearized cosmid was then ligated with the 6.81 kb DraI 
fragment from pOJ436. This fragment contains an origin of transfer (oriT), an apramycin 
resistance marker, and elements of the phiC31 attp-attB integration system needed for integration 
into diverse Streptomyces sp. Retrofitted cosmids were transformed into E. coli S17.1 and 
conjugated into Streptomyces using published protocols (Feng, Khallifidas et al. 2011).  
 
4.4.4 Overlapping clone recovery and bioinformatic analysis 
Anza Borrego (California) and AZ (Arizona) desert soil eDNA libraries were screened for 
overlapping clones for AB1215, AB1449 and AZ1237. These were subsequently identified from 
the corresponding library using clone-specific primers designed to recognize the sequence at one 
or both ends of the original pathways. The PCR protocol used was as follows: denaturation (95 
°C, 5 min), 36 standard cycles (95 °C, 30 s; 55 °C, 30 s; 72 °C, 40s), and a final extension step 
(72 °C, 7 min). Overlapping eDNA cosmids were recovered from these pools using the serial 
dilution method outlined above. The following primer sets were used: 
AB1215 gene cluster  
One overlapping clone for AB1215 pathway was identified in the AB library 183 sub-pool using 





AB1449 gene cluster  
One overlapping clone for AB1449 pathway was identified in the AB library 647 sub-pool using 






AZ1237 gene cluster  
Two overlapping clones for AZ1237 pathway was identified in the AZ library subpools 2224 and 








All cosmids were sequenced by 454-pyrosequencing. ORFs (open reading frames) were 
predicted using MetaGeneMark (Zhu, Lomsadze, and Borodovsky 2010) and predicted ORFs 
were annotated by Blast search and Pfam domain analysis.  
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4.4.5 eDNA clone sequencing 
PKS containing cosmids recovered from the eDNA libraries were initially sequenced by 454 
pyrosequencing (Roche) at the Memorial Sloan Kettering Cancer Center Genomics Core 
Laboratory. All overlapping cosmids and TAR constructs were sequenced using IonTorrent 
Personal Genome Machine (PGM). The size and deduced role of the open reading frames 
(ORFs) were predicted using MetaGeneMark (Zhu et al. 2010), and predicted ORFs were 
annotated by Blast search and Pfam domain analysis. MacVector was used for sequence 
manipulation. 
 
4.4.6 Transformation-associated recombination (TAR) reassembly of three overlapping eDNA 
clones 
Pathway-specific capture vector construction. 
 
The overlapping eDNA cosmid clones were assembled into a single bacterial artificial 
chromosome (BAC) clone using transformation-associated recombination (TAR) in yeast and the 
pTARa BAC shuttle vector. The pathway-specific TAR capture vector was constructed using 
InFusion cloning methodology (Clontech). ~500 bp upstream and downstream homology arms 
were amplified from each cosmid. The homology arms needed for TAR recombination were 
generated using the following primers: 
 
AB1215 gene cluster (AB1215 and AB189)  
AB1215UPS_FW (5′- CTATCGATCTCGAGGGTGGTGGACATCGACCTGAT-3′),  
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AB1215UPS_RV (5′- ATGACCGATGTTAACCGTTAATTTCCTCGCACCGG-3′),  
AB183DWS_FW (5′-GTTAACATCGGTCATCGGTCGAATGC- 3′),  
AB183DWS_RV (5′- CCCTGCAGGAGCTCGATTTCCAGGCTCAGCTCGTC-3′)  
AB1449 gene cluster (AB1449 and AB647)  
AB1449UPS_FW (5′- CTATCGATCTCGAGGTTGGAAACCAGCCGGATGAC-3′),  
AB1449UPS_RV (5′- GACCCGGATGTTAACCGTCCCTCAAGCCGTTCTAA-3′),  
AB647DWS_FW (5′-GTTAACATCCGGGTCAACTCCTCGAT- 3′),  
AB647DWS_RV (5′- CCCTGCAGGAGCTCGCATCTGTTACGCCAGCCAGA-3′)  
AZ1237 gene cluster (AZ2250, AZ1237 and AZ2224)  
AZ2250UPS_FW (5′- CTATCGATCTCGAGGGCTGCGGCAATGAACATGAT-3′),  
AZ2250UPS_RV (5′- CAGTCCTCTGTTAACGCCTGGACCAACAACACCAT-3′),  
AZ2224DWS_FW (5′-GTTAACAGAGGACTGTTCGTGCTGAC- 3′),  
AZ2224DWS_RV (5′- CCCTGCAGGAGCTCGATGGACAGTTCGGTGGTGTC-3′)  
 
TAR cloning and pathway assembly 
TAR primers include 15 bp sequences (underlined) that overlap with BmtI/SphI linearized 
pTARa capture vector. Primer ending with UPS_RV was designed to contain a 15 bp overlap 
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(underlined) with the primer ending with DWS_FW primer and an HpaI site (bold), which was 
added to facilitate the subsequent linearization of the pathway-specific pTARa capture vector. 
Gel-purified amplicons (Qiagen) and BmtI/SphI linearized pTARa were combined in a standard 
InFusion cloning reaction (Clontech) to make the pathway-specific capture vector. 
 
For TAR assembly, 200 ng of DraI-digested cosmids were mixed with 100 ng of the HpaI-cut 
pathway-specific capture vector and then transformed into 200 µL of Saccharomyces cerevisiae 
CRY1-2 spheroplasts prepared according to published protocols (Feng, Khallifidas et al. 2011). 
Transformed spheroplasts were mixed with synthetic complete (SC) top agar (1 M sorbitol, 1.92 
g/L synthetic complete uracil dropout supplement, 6.7 g/L yeast nitrogen base, 2% glucose, and 
2.5% agar) and overlaid onto SC uracil dropout plates. Plates were incubated at 30 °C for 72 h. 
DNA was prepared from 12 yeast colonies using a zymolyase lysis protocol (ZYMO 
RESEARCH) and screened by PCR with primers designed to recognize sequences from 
individual cosmids. A BAC clone that was “PCR positive” with all the primer sets was 
electroporated into E. coli EPI300 (Epicentre). DNA isolated from the resulting E. coli was fully 
sequenced by IonTorrent Personal Genome Machine (PGM) and confirmed to be faithful 
reassemblies of the overlapping cosmid clones.  
 
4.4.7 Heterologous expression and analysis 
The cosmid clones (AB1215, AB1449 and AZ1237) as well as the BAC constructs (BAC-
AB1215/183, BAC-AB1449/647 and BAC-AZ2250/1237/2224) were transformed into E. coli 
S17.1 and conjugated into Streptomyces albus. Spore stocks of S. albus transformed with the 
cosmid or BAC clone was inoculated in 125 mL baffled flasks containing 50 mL of R5A media 
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(Zhu et al. 2010) (for 1 L: 100 g sucrose, 0.25 g K2SO4, 10.12 g MgCl2•6H2O, 10 g glucose, 
0.1 g casamino acids, 5 g yeast extract, 21 g MOPS, 2 g NaOH, 2 mL R2YE trace elements) and 
grown at 30 °C (200 rpm) for 7-10 d. Cultures were then extracted twice with an equal volume of 
ethyl acetate. The dried extracts were dissolved in methanol (2-4 mL/L of culture). The sample 
was then dried, redissolved in 1-2 mL of methanol. The resulting ethyl acetate extract was 
compared by LC-MS to the extract from a similarly grown culture of S. albus transformed with a 
pTARa empty vector control (HPLC conditions: 30 min gradient from 5% to 100% aqueous 
acetonitrile containing 0.1% formic acid, C18, 4.6 mm × 150 mm, 1 mL/min). 
4.4.8 Cloning of the rhamnose biosynthetic genes 
pIJRham expression vector containing the rhamnose biosynthetic operon (oleL: dNDP-4-keto-6-
deoxyglucose 3,5-epimerase, oleS: dNDP-D-glucose synthase, oleE: dNDP-glucose 4,6-
dehydratase and oleU: dNDP-4-ketohexulose reductase) was transformed into E. coli S17.1 and 
then shuttled into S. albus/BAC-AB1215/183, S. albus/BAC-AB1449/647 and S. albus/BAC-
AZ22250/1237/2224 by intergenic conjugation. This expression vector utilizes an orthogonal 
phage integration system (ΦBT1) and resistance gene (hygromycin) to those present on the BAC 
clones thereby allowing the co-integration of both the biosynthetic gene cluster and the rhamnose 
biosynthetic operon into distinct chromosomal sites in S. albus to generate S. albus/BAC-








5.1 Better bioinformatics 
Considering the recent explosion in the number of studies taking advantage of next-generation 
sequencing to explore metagenomic or taxonomic diversity of environmental microbiome, we 
need better tools to best interpret the data. As of now, interpretation of sequencing data mostly 
relies on sequence similarity, on the premise that near identical or similar DNA sequences 
translate to identical or similar protein function. Although this general paradigm is valid, as 
many studies have demonstrated, our current knowledge and annotations of protein-coding genes 
is less than comprehensive. A large number of genes in newly sequenced microorganisms cannot 
even be identified or annotated (Roberts, 2004). This impedes our ability to use metagenomics to 
study microbial genome diversity as well as functional analysis thereof. Although efforts are 
being made to improve the coverage of known genome-derived proteins, we need new 
technology to link experimental data to large families of similar proteins. The bias in the genome 
and protein databases is one major hindrance to the use of existing annotations. For example, a 
large proportion of organisms being sequenced come from the medical community.  
 
Another major concern is that different annotation pipelines potentially produce different results. 
Simple processes like comparative genomics routinely require re-analysis of all data involved in 
the comparison (Dinsdale et al., 2008). Attempts to create a simple exchange language for 
microbial genome analysis have not been successful. With large volumes of data, re-analysis is 
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not feasible because data analysis cost will exceed the sequencing cost. Metagenomic analysis 
databases need to expand and be better curated to have a sustained annotation infrastructure. 
 
5.2 Large insert metagenomic libraries 
A major hurdle to natural product discovery through metagenomics is the recovery of complete 
biosynthetic gene clusters from the environment. Natural product biosynthetic gene clusters can 
vary in size from a few kilobases to more than 100 kilobases. We have successfully gained 
access to some of the natural products encoded in the genomes of uncultured bacteria using 
metagenomic techniques. However, the inability to construct very large eDNA libraries with 
inserts big enough to capture large biosynthetic pathways on individual clones, has been limiting. 
If individual clones could capture  >100 kilobases of contiguous eDNA, we would have much 
better chance of finding novel chemistry in nature. An obvious solution to this issue is to 
construct libraries with larger insert clones that can be used to capture large natural product gene 
clusters. It’s now routine to construct of 30–40 kb insert cosmid libraries from environmental 
DNA samples. However, making libraries of large insert clones has been challenging. Bacterial 
artificial chromosomes or BACs have been used to construct large insert DNA libraries. 
However, BAC-based metagenomic libraries are generally two to three orders of magnitude 
smaller than those constructed using cosmid-based cloning strategies (Liles, Williamson et al. 
2008). It was therefore assumed that the overall coverage had to be compromised in order to 
have larger contiguous fragments of DNA. However, advancements in BAC cloning have led to 
the construction of libraries containing more than one million clones (Magbanua, Ozkan et al. 
2011). Advent of such technology will inevitably revolutionize the field of metagenomics as a 
natural product discovery platform.  
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5.3 Activation of silent biosynthetic gene clusters 
The ongoing exponential growth of genome sequencing data has led to the discovery of many 
natural product biosynthesis pathways for which no actual molecule has been characterized. The 
biosynthesis of natural products is highly regulated and these clusters often remain silent under 
laboratory conditions (Jensen, Chavarria et al. 2014). The regulation is conducted through 
dozens of pleiotropic regulatory genes and pathway-specific regulators (Bibb and Hesketh 2009). 
They form a complex network in response to a variety of physiological and environmental cues. 
The conditions under which a given gene cluster is naturally expressed are largely unknown. A 
number of technologies based on genetic engineering are available to induce silent genes. Most 
of the successful approaches have been based on generation of gene “knock outs”, promoter 
exchange, overexpression of transcription factors or other pleiotropic regulators (Kallifidas and 
Brady 2012; Scherlach and Hertweck 2009). Using engineered nucleases is another important 
new approach to regulate gene expression in prokaryotes through transcriptional control. 
Clustered, regularly interspaced, short palindromic repeat (CRISPR) technology is pioneering 
this approach in combination with RNA-guided nucleases, such as Cas9, to edit an organism’s 
genome with customizable specificities. Genome editing mediated by CRISPR-Cas9 systems has 
been successfully exploited to achieve programmable transcription activation and repression of 
bacterial gene expression (Bikard, Jiang et al. 2013). In a recent report from Brady lab, yeast 
homologous recombination have been successfully used to exchange all native promoters in 
silent gene clusters with constitutively active promoters (Montiel, Kang et al. 2015) which led to 
the induction of an otherwise silent pathway. Strategies based on epigenetics has opened new 
avenues for the elucidation of the regulation of secondary metabolite formation and will certainly 
continue to play a significant role for the elucidation of cryptic natural products (Brakhage 
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2013). Then there are simulation strategies that attempt to recreate natural habitat by co-
cultivation of microorganisms from the same ecosystem (Bertrand, Bohni et al. 2014). Although 
a number of such strategies are being explored to activate silent gene clusters, we are in need of a 
robust technology that will allow detailed studies across multiple different types of biosynthetic 
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